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The Road Not Taken
Two roads diverged in a yellow wood,
And sorry I could not travel both
And be one traveler, long I stood
And looked down one as far as I could
To where it bent in the undergrowth; 
Then took the other, as just as fair,
And having perhaps the better claim
Because it was grassy and wanted wear,
Though as for that the passing there
Had worn them really about the same,
And both that morning equally lay
In leaves no step had trodden black.
Oh, I kept the first for another day! 
Yet knowing how way leads on to way
I doubted if I should ever come back.
I shall be telling this with a sigh
Somewhere ages and ages hence:
Two roads diverged in a wood, and I,
I took the one less traveled by,
And that has made all the difference.
(Robert Frost 1874-1963)

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for the metastatic process, as well as tumor cell proliferation and cell cycle regulation. 
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ABSTRACT 
Background: 
Endometrial cancer is diagnosed early and has in general a good prognosis. The more 
important it is to diagnose and treat the poor-prognosis cases. Therapy of endometrial 
carcinoma patients per today is to a large extent empirically based. Improvements on 
therapeutic strategies with more personalized focus are needed. Preparing the ground for 
later clinical studies, by combining clinico-pathologic and molecular data from preclinical 
studies and cancer patients, is an important step to individualize therapy in cancer. 
The incidence of endometrial cancer is increasing and the prognostic categorization used 
in clinical practices today is suboptimal for separating patients according to survival. 
Despite a focus on translational research in endometrial cancer for some decades, it has 
proven difficult to bring new biomarkers to the clinic to improve prognostication and 
prediction of therapy response in this cancer type. Endometrial cancer is behind other 
cancer types as breast, lung and colorectal cancer in clinical application of molecular 
classification of tumors to select patients for targeted therapy. Better tumor biological 
understanding of subgroups, applicability of prognostic markers in a routine clinical 
setting, and targets for therapy including markers predicting response to such, is important 
to improve personalized treatment strategies to benefit the endometrial carcinoma 
patients.   
Main objectives: The main objective was to study biomarkers potentially associated with 
endometrial carcinoma progression, to assess their potential as prognostic markers and 
explore on targets for therapy associated with pathologic expression of these markers. By 
this, we aimed to provide a rationale for further testing of candidate markers as prognostic 
and predictive markers in clinical trials. Also, we wanted to focus on biomarker 
implementation through an important step in the stair-case from research to clinical use; 
biomarker validation in independent patient series and in a routine clinical setting.  
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Materials and methods: Overall, subsets of one retrospective and one prospective 
patient cohort were analyzed (Paper I-IV), in addition to an external gene expression 
microarray (Paper II) and endometrial cancer data from The Cancer Genome Atlas 
(TCGA, Paper IV), with comprehensive clinico-pathologic and follow-up annotations for 
all series. DNA oligonucleotide microarrays were analyzed (Paper I-IV). ERĮ and 
pStathmin(S38) immunostaining was performed (Paper II and III, respectively). Also, 
previously published data were included (e.g. EMT markers, data on vascular invasion, 
proliferation markers, PIK3CA sequencing data, Stathmin and SNP array data). RNA 
sequencing for gene expression levels were retrieved from 333 endometrial carcinoma 
samples in The Cancer Genome Atlas (TCGA).  
Results: DNA aneuploidy was associated to higher age at diagnosis, non-endometrioid 
histology and high histologic grade in both series studied, and with independent 
association with reduced survival in multivariate analyses. We found the research and 
routine diagnostic series to be comparable, with no significant differences in distribution 
in standard clinico-pathological variables (Paper I). 
ERĮ-low tumors were associated with aggressive endometrial cancer and reduced 
survival in 4 independent patient series. Transcriptional differences based on ERĮ status 
revealed pathways, single genes and transcription factors linked to epithelial-
mesenchymal transition (EMT) enriched in ERĮ negative tumors, also validated in an 
external gene expression data set and validated by mRNA and immunohistochemistry in 
two independent patient series. ERĮ-low tumor status was also significantly correlated to 
various markers for PI3Kinase pathway alterations.  Furthermore, the gene expression 
signatures of PI3K/mTOR inhibitors were correlated to ERĮ-low gene signatures in two 
independent patient series (Paper II). 
High pStathmin(S38) immunostaining associated with an aggressive clinico-pathologic 
phenotype and reduced survival, in both the investigation and validation cohorts. Gene 
expression patterns related to cell cycle progression were enriched in pStathmin(S38)-
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high cases. pStathmin(S38) also correlated with a panel of established markers for tumor 
cell proliferation: Ki67, mitotic count and S-phase fraction. Gene expression signatures 
representing effect of PI3K/mTOR and HSP90 inhibitors associated with a 
pStathmin(S38)-high gene expression signature. High pStathmin(S38) correlated 
significantly with several potential markers for PI3K activation (Paper III). 
The 29-gene signature score validated to identify patients with increased risk of 
recurrence, also in patient subgroups with presumed favorable outcome. The 29-gene 
endometrial carcinoma recurrence score (ECARS) also associated with clinico-pathologic 
data of aggressive endometrial cancer. ECARS validated to predict overall survival in 332 
cases from The Cancer Genome Atlas (TCGA) database. High ECARS associated with 
vascular invasion and measures for EMT and potential measures for PI3K pathway 
activation. Assessing ECARS and an EMT signature in metastatic lesions demonstrated 
an increase of theses signatures from primary to metastatic tumors (Paper IV). 
Conclusions: DNA aneuploidy identifies aggressive endometrial carcinoma and predicts 
poor outcome, also in a routine clinical setting (Paper I). 
Low ERĮ in endometrial carcinoma is associated with epithelial-mesenchymal transition, 
vascular invasion and PI3K alterations (Paper II).     
High pStathmin(S38) associates with high tumor cell proliferation and measures for 
PI3Kinase activation in endometrial carcinomas (Paper III). 
The endometrial carcinoma recurrence score (ECARS) validates to identify endometrial 
carcinomas with shorter recurrence free survival. ECARS increases from primary to 
metastatic lesions and is associated with measures for PI3Kinase activation and epithelial-
mesenchymal transition (Paper IV).  
Low ERĮ, high pStathmin(S38) and high ECARS predict aggressive endometrial 
carcinomas and reduced survival, and may suggest treatment with PI3K/mTOR and or 
EMT inhibitors in clinical trials (Papers II, III and IV). 
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1. INTRODUCTION 
Cancer - a disease of unregulated cell growth and with a potential of cancer cell invasion 
into neighboring organs as well as spread to distant organs. Cancer may develop in any 
tissue originating from embryonic mesoderm, ectoderm or endoderm, and is of many 
today regarded as a “genetic disease at the cellular level”,1 as genetic alterations in 
somatic cells are thought to be required for initiation of the carcinogenic process in the 
development from normal to cancerous tissue. There is a large range of clinical 
presentations in cancers, depending amongst other on the cancer type, localization and 
stage of the disease. 
Endometrial carcinoma is an epithelial cancer, developing in the epithelial lining of the 
uterine cavity, with a potential to invade into the myometrium and cervical stroma and 
spread to distant body sites.  
 
1.1 Epidemiology  
Incidence  
Worldwide, cancer has a major role in the burden of diseases, being the number one cause 
of death in developed countries and the second most frequent cause of death in 
developing countries. Almost 13 million new cases and 7.6 million cancer deaths were 
estimated in 2008.2 Endometrial cancer is one of the most common cancer types in 
women and the 4th most frequent cancer type in women of developed countries after 
breast, colorectal and lung cancer,2 affecting more than 140 000 new women per year. 
Endometrial cancer is also the most frequent pelvic gynecologic cancer type in the 
Western world.3,4  
The endometrial carcinoma incidence is reported to be increasing in Europe.5 The age 
adjusted incidence rate (new cases per 100 000 person years) in Norway is 16.5/100 000 
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person-years4 (Figure 1), and has increased from 7.0 in 1955-59 through 12.2 in 1980-85 
to 16.4 in 2005-2009 (Figure 2).4 
Figure 1. Estimated age-standardized incidence rate of corpus uteri cancer per 100 000 
person-years (adapted from http://globocan.iarc.fr) 
 
 
In cancer and death registries, endometrial carcinomas are recorded within the group of 
uterine cancer, indicating that the crude numbers of endometrial carcinomas are lower 
than the reported overall numbers for uterine cancers, the latter also including uterine 
sarcomas in the statistics.4 Uterine sarcomas are demonstrated to comprise 3-9% 
(depending on histological definition) of all uterine cancers,6,7 and to occur with a 
relatively stable incidence of 0.3-0.4 per 100 000/year in the Nordic countries,8 
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supporting that the observed increase in the numbers of uterine cancer over the same 
period mainly reflects the increased incidence of endometrial carcinoma. 
Figure 2. Incidence, mortality and survival rates from uterine cancers in Norway 1965-
2008.4  
 
 
Survival  
The ultimate goal when treating cancer patients is to extend life expectancy with as good 
life quality as achievable, for a period as long as possible. It is important to discuss which 
end-points are best suited when reporting on cancer prognosis, and thereby as indirect 
measures for effects of cancer therapy. In general, disease/cancer specific survival is 
described by time from diagnosis to death from cancer. Overall survival time, the time 
from diagnosis to death of any cause, is suggested to better reflect the overall efficacy of 
therapeutic interventions, also accounting for potential therapeutic side effects with 
survival impact. Effects on survival after recurrences also impacts overall survival. As 
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such, progression free survival (for patients with advanced cancers) and recurrence free 
survival (for patients with localized cancers), are considered to be surrogate measures for 
overall survival, used as secondary end-points in clinical trials, where overall survival is 
the primary end-point when evaluating effects from interventions.    
In endometrial cancer, overall survival has increased over the last 40 years, from 72.8% to 
83.5% (for all stages).4 The increase in overall survival is seen within each of the various 
stages of the disease (Figure 3). 
 
Figure 3. Five-year relative survival (%) from uterine cancer in Norway (1969-2008). 
Survival rates stratified according to disease stage (based on numbers from Cancer 
Norway2008).
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1.2 Etiology and risk factors 
“Correlation does not imply causation” (RA Fisher 1890-1962)
It is generally accepted that cancer as well as other diseases, are “caused” by certain 
influences. Various presumed “causes” have directed approaches to both diagnostics and 
treatment throughout the medical history.9 “Etiology” is in medicine regarded as the cause 
of origin of a disease, and the studies of such. Classification of etiologic factors into 
genetic and acquired is commonly applied.9 For only a few diseases, the simple link “one 
agent leading to one disease” is valid, exemplified by some infections and diseases caused 
by changes in one single gene.  Many diseases, including cancer, are today regarded to 
have multifactorial etiology.9 
 
Genetic factors 
Cancer is considered “a genetic disease at the cellular level”,1,10 and was only a few years 
ago considered to be of monoclonal origin.11 For many cancer types there is now strong 
evidence for cancer being a polyclonal disease.12 Endometrial carcinoma is a 
heterogeneous neoplasia, associated with a variety of genetic alterations.   
Genetic causes for cancer can be divided into two groups: hereditary (covered in this 
chapter) and somatic (covered in chapter 1.3). Overall, the life-time risk for developing 
endometrial carcinoma is approximately 1.6%.2 The majority of cases are sporadic, but a 
subgroup of approximately 5% of endometrial carcinomas develop due to a genetic 
predisposition caused by inherited mutations (i.e. in germ cells ) of cancer-related genes.13 
Patients with the inherited diseases Lynch syndrome, Cowden syndrome or Peutz-Jeghers 
syndrome are all at increased risk of developing endometrial cancer.  
22

Lynch syndrome 
Hereditary non-polyposis colorectal cancer (HNPCC), also called Lynch syndrome, is an 
autosomal dominant disease caused by pathogenic germ line mutations in DNA mismatch 
repair (MMR) genes.14 The prevalence of such mutations is 1:500-1:1000.14 The first 
description of the original HNPCC family took place 100 years ago.15 The disease was 
recognized as a syndrome and further defined in the 1960-70s. Patients with Lynch 
syndrome are at increased risk of several cancers; colorectal, endometrial, gastric and 
ovarian cancer, with highest lifetime risk for women (40-60%, 40-60%, 13% and 6-12%, 
respectively).16,17 The prognosis for endometrial cancer related to HNPCC is similar to 
sporadic endometrial cancer.18 A proposed screening program for women with Lynch 
syndrome includes colonoscopy once every 1-2 years, endometrial sampling once a year, 
urine cytology once a 1-2 year, and general history and examination yearly, starting from 
21-30 years. Hysterectomy and ovarectomy are considered when the woman does not 
want (more) children.19 Yearly screening with endometrial biopsy for women with known 
germline mutations in MMR genes is recommended by some.20 However, in general the 
effectiveness by diagnosing these early stages of cancer is debated.21  
Cowden syndrome and Peutz-Jeghers syndrome  
Cowden syndrome is autosomal dominant inherited and characterized by multiple 
hamartomas occurring in different tissues. The incidence of Cowden syndrome is 
estimated to 1:200 000-250 000.22 Cowden syndrome patients have increased risk of 
malignancies, in particular breast, thyroid and endometrial cancer,23 and have an 
endometrial cancer lifetime risk of 5-10%.24 The majority of Cowden syndrome patients 
have germ line PTEN mutations (~80%),22 potentially explaining the increased cancer 
risk. 
Multiple hamartomatous polyps in the gastrointestinal tract and mucocutaneous 
pigmentation characterize the Peutz-Jeghers syndrome,23 in addition to risk of developing 
gastrointestinal and other cancer types. The incidence of this syndrome is 1:50 000-250 
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000. Autosomal dominant inherited STK11 mutation is seen in ~90% of the patients.25 
The lifetime risk of developing endometrial carcinoma is 9% in this patient group.26     
Screening for endometrial cancer in both Cowden and Peutz-Jeghers syndromes are at 
present being discussed, but per December 2012, no screening guidelines are 
implemented.23  
 
Acquired factors 
90-95% of endometrial carcinomas are sporadic occurring cancers.14 Bokhman suggested 
in a clinical, descriptive study of 366 patients, two distinct pathogenetic types of 
endometrial carcinoma.27 Diabetes, hypercholesterolemia, hypertension and overweight 
were frequently observed in a large fraction of the patient series (60-80%). These patients 
more often developed endometrial carcinoma with concurrent endometrial hyperplasia, 
and were associated with low histologic grade, superficial myometrial infiltration and 
response to progestagens. The tumor was considered cancer of “the first type”, later 
named Type I endometrial carcinoma.28,29 In the “second type”, metabolic disturbances 
amongst the patients were absent, tumors were more often of high histologic grade with 
deep myometrial infiltration, and more metastatic spread occurred. Also, a different 
association with survival was noted between the two patient groups; the “second type 
cancer” was associated with reduced survival. The categorization into type I and II is still 
the major classification of endometrial carcinoma in clinical use today, although several 
molecular characteristics associated with the type I versus type II distinction have been 
reported.30 
One of the early published reports on co-occurring prolonged exogen estrogen stimulation 
and development of endometrial cancer in patients is from 1946.31 The study is a case-
report of a 45 year old woman receiving unopposed estrogen therapy over 8 years, 
developing endometrial cancer by end of therapy. The case-report led to the hypothesis 
that endometrial cancer develops because of unopposed estrogen therapy. The surgeon G. 
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Beatson (1848-1933) is, however, recognized as the first to present the hypothesis that 
ovarian hormones play an important role in the cause of cancer, based on observational 
studies in breast cancer patients.32 The description of how oophorectomy in patients with 
advanced breast cancer improved the performance with respect to cancer dissemination 
came even before the concept of hormones was set forth. The functional roles of estrogen 
in cancer development have since then been extensively studied in epidemiological, 
clinical and experimental studies.33-36 It is now generally accepted that excess estrogen 
relative to progesterone plays an important role for development of endometrial cancer.37  
In the reproductive age, estrogens are synthetized and secreted primarily by the ovaries, 
with contributions also from adipose tissue and adrenal glands. In the postmenopausal 
phase, the majority of circulating estrogen is synthesized by peripheral aromatization of 
adrenal androgens. Intratumoral estrogen synthesis is also suggested being important in 
endometrial cancer.35 Surplus estrogen, relative to progesterone, promote angiogenesis38 
and endometrial cell proliferation,39 and inhibits apoptosis.40,41 Progesterone is considered 
to counteract the proliferative effects of estrogen, contributes to cellular differentiation42 
and inhibition of cancer cell invasion.43 A relative estrogen/progesterone excess may 
appear as a consequence of excess estrogen and/or progesterone deficiency. Overweight, 
unbalanced hormonal replacement therapy only replacing estrogen, but not progesterone, 
persistent anovulation, and nulliparity are conditions that lead to increased circulating 
estrogen, and are associated with increased endometrial cancer risk.44-50  
Strong associations between obesity and occurrence of endometrial cancer are 
demonstrated,44,51 and increasing obesity is viewed as a major contributor to the 
increasing incidence of endometrial carcinoma in the Western world.28 Various 
mechanisms underlying this observation are suggested, conveying through the excess of 
estrogen relative to progesterone: Increased aromatase activity in fatty tissue together 
with reduced levels of Sex hormone-binding globulin (SHBG) leads to increased 
bioavailable estrogen,48 and increased ovarian androgen synthesis leads to chronic 
anovulation and decreased levels of progesterone.48 Obesity is also associated with 
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increased levels of insulin and Insulin-like growth factor-1 (IGF-1); both being ligands of 
receptors potentially activating the PI3K signaling pathway and downstream key 
processes in the carcinogenesis, such as proliferation and cell survival.45,52 Occurrence of 
endometrial cancer is also associated with hypertension and diabetes mellitus,53 but their 
role as causal factors is not clear.45  
Breast cancer patients treated with the estrogen receptor antagonist Tamoxifen are 
associated with a two-fold increased risk of endometrial cancer, also dependent on 
duration of therapy.54-56  
Late age at menarche, early age at first birth, last pregnancy at relatively high age, high 
number of children, longer (accumulative) period of breastfeeding, and use of 
combination oral contraceptives are associated with decreased risk of endometrial 
cancer.37 Habitual factors such as smoking and physical activity are also associated with 
reduced risk of endometrial cancer.57-60 The antiestrogenic effects of smoking through 
altered hormonal metabolism, weight loss and earlier menopause, are suggested 
mechanisms for this observation. Combined oral contraceptives are associated with 
reduced risk of endometrial carcinoma (ever use associated with 30% lower risk).61,62   
 
1.3 Tumor biomarkers in endometrial carcinomas  
Cancer has been characterized by eight hallmarks contributing to the “cancer phenotype”: 
Self-sufficiency in growth signals, insensitivity to anti-growth signals, limitless 
replicative potential, evasion from apoptosis, sustained angiogenesis, tissue invasion and 
metastasis.10 Re-programming of energy metabolism and evasion from immune 
destruction are two major characteristics more recently added to the list of cancer 
hallmarks. Underlying these hallmarks are a broad range of genetic and epigenetic 
aberrations as well as dysregulated communication between cancer cells themselves and 
between cancer cells and cells in the surrounding tumor microenvironment.10 Endometrial 
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cancer is a heterogeneous disease, reflected in a variety of molecular alterations described 
for this cancer type.63,64 In the following, a presentation of some of the mentioned 
hallmarks and underlying alterations is given and related to the endometrial carcinoma 
tumor biology. 
 
Enabling characteristics in endometrial carcinomas 
Genomic instability  
Mutations 
The human genome is dynamic, and millions of DNA damaging events and replication 
errors occur daily.65 A highly efficient genome maintenance system, including detection 
and repair mechanisms, functions such that mutations are not frequently found in each 
cell generation in normal tissues.10 Chromosomal instability  is demonstrated in cancer, 
where the chromosomal structure and content changes over time, with high rate compared 
to normal cells.66 A cancer “mutator phenotype” is suggested, where mutations in genes 
crucial to maintain a normal genotype occur, such as the DNA repair genes, and thereby 
contribute to the large amount of mutations present in cancer.65  
Short, repetitive DNA sequences throughout the genome are called microsatellites. These 
sequences are susceptible to replication errors, and if loss of function of the DNA repair 
genes occurs, there is high risk of mutations in these satellites, denoted microsatellite 
instability (MSI)67,68 and regarded as a form of genomic instability.66 MSI occur in 11-
45% of endometrioid endometrial carcinomas.69 HNPCC families carry germ line 
mutations in the DNA mismatch repair genes MLH1 and MSH2, potentially contributing 
to the increased risk of both colorectal and endometrial cancer.63 In sporadic endometrial 
cancer, some of the DNA mismatch repair genes are demonstrated to be silenced by 
promoter methylation.63  MSI is more frequent in Type I endometrioid carcinomas (20-
45%), compared with 0-5% in type II carcinomas.64 
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Depending on the location of a mutation and its amino acid effect, various mutations of a 
gene exhibit different effects. Mutations in the promoter region of a gene may alter how 
the gene is transcribed (more/less expressed, and to other times or in other locations 
compared to the non-mutated state). Missense and nonsense mutations in coding regions 
of the genome, coding for different amino acids and stop codon, respectively, may affect 
the protein structure and thus alter protein function.70 Silent mutations code for similar 
amino acids or amino acids that do not imply functional protein alterations. Growth 
signaling may be activated by mutations in oncogenes or tumor suppressors involved in 
regulating such signaling pathways.66 A wide range of mutations are described in 
endometrial cancer (http://cancer.sanger.ac.uk/cosmic/browse/tissue?sn=endometrium). 
PIK3CA, KRAS, FGFR2, TP53 and PTEN mutations are identified with varying 
frequency in type I and type II tumors (Table 1).64,71 Several PIK3CA mutations are 
suggested as activating mutations with regard to PI3K signaling,72 and a mutation in 
PIK3CA exon 20 (H1047R) has recently been suggested as a predictive marker for 
response to PI3K inhibitors in endometrial carcinoma.73 Recent whole exome sequencing 
of serous endometrial carcinoma have identified TP53, PIK3CA mutations (82% and 
24%, respectively) together with mutations in chromatin remodeling genes and ubiquitin 
ligase complex genes.74,75 Dysfunctional chromatin remodeling and ubiquitin ligase is 
regarded to have important roles in carcinogenesis and cancer progression.76,77   
The functional implications from various mutations are to some extent studied in 
experimental models and provide a basis for the understanding of effects from similar 
mutations in human. Still, many of the mutations found in human cancer are not 
functionally described in experimental models and are only associated with cancer and 
cancer phenotypic measures. As the whole exome sequencing is emerging within cancer 
research and more cancer associated mutations are identified, the functional implications 
and relevance for drug response of these mutations are important objects for future 
studies. 
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Somatic copy number alterations 
Somatic copy number variations are common in cancer and may contribute to drive the 
development of cancer.78 Salvesen et al characterized 57 endometrial carcinomas by gene 
expression arrays and 76 tumors by copy number profiling, and found oncogenes such as 
PIK3CA, EGFR, MYC, KRAS, ERBB2 and AURKA significantly amplified across the 
samples studied.79 Also, a tumor suppressor (FBXW7) was identified deleted in this 
population.79 Two other studies assessed genome wide copy number alterations in serous 
and endometrioid subtypes and confirmed PIK3CA and KRAS amplifications and deletion 
of FBXW7 in endometrial cancer.74,80 In a study by Murayama-Hosokawa et al, the extent 
of the copy number alterations was categorized: Tumors were presented as chromosomal 
instability (CIN) negative, i.e. no copy number alterations, CIN-intermediate and CIN-
extensive (1-4 and  5 loci of copy alterations, respectively). Patients with CIN-extensive 
tumors experienced significantly poorer survival as compared to those with CIN negative 
or intermediate tumors. In addition to standard copy number gain and loss, this study also 
described presence of copy number neutral (CNN) LOH, denoting loss of one allele and 
gain of the opposite allele, in CDKN2A, PTEN and TP53.80               
Epigenetic alterations; methylation 
“Epigenetic alterations” denotes inheritable  changes in gene expression and phenotype 
not due to altered nucleotide sequence.81 Methylation - attachment of methyl groups to 
cytosine in CpG sequences located in promoter regions and within gene exons and 
introns, is one of the epigenetic alterations associated with cancer, and both loss and gain 
of methylation may contribute to increased and decreased/silenced transcription, 
respectively.81 Methylation is suggested to be as important as mutations for reduced 
transcription of tumor suppressor genes.1  
In a study of the methylation pattern of 24 tumor suppressor genes in the carcinogenic 
process in endometrial cancer, promoter methylation increased from normal endometrium 
to simple and complex hyperplasia.82 Hypermethylation of the DNA mismatch repair 
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gene MLH1 is associated with MSI in endometrial cancer, particularly the endometrioid 
subtype, and is suggested to be a cause of MLH1 silencing, as demonstrated in cancer cell 
lines.83,84 Methylation of tumor suppressor genes such as PTEN, CDKN2A, RASSF1A and 
APC have been reported in endometrial carcinomas with frequencies in the range of 11-
85%.83 Also, low expression of the cell adhesion marker E-cadherin (CDH1) is suggested 
to occur by promoter hypermethylation.83 Silencing of these genes by methylation is more 
frequent in type I than type II cancers, and it is suggested that hypermethylation has a 
stronger impact on the carcinogenesis in type I than type II endometrial carcinomas.83  
Non-coding RNA:  
Over the last years, the importance of non-protein coding RNA to biological processes 
has been recognized. Micro-RNA (miRNA) is known to post-transcriptionally repress 
gene expression at the level of translation by binding to mRNA, and is thus able to 
regulate multiple gene targets.85 A global down-regulation of miRNA expression is 
demonstrated in cancer,86 and specific miRNA alterations are associated with various 
cancer types and may function as oncogenes and tumor suppressors.85 MiRNAs 
alterations in cancer are suggested to affect genomic instability and DNA repair 
mechanisms, contributing to the overall genomic instability seen in cancer.86 MiRNAs are 
also suggested as metastatic activators.87 The miR-200 family is presented as tumor 
suppressors and down-regulation of these is further linked to epithelial-mesenchymal 
transition (EMT) and the invasive process.88 In line with this, the miR-200 family is 
demonstrated to be down-regulated in the mesenchymal part of carcinosarcomas,89 and 
studies of endometrial cancer cell lines have demonstrated a link between low expression 
of miR-200 family members, increased ZEB1 expression and further low expression of E-
cadherin.90       
Dysregulated pathways
Several of the above mentioned enabling characteristics have the potential to activate 
specific signaling pathways that may promote cancer initiating processes and alterations 
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linked to cancer progression. By binding of extracellular growth factors to corresponding 
receptors and the following intracellular signal transduction of the growth signals to the 
nucleus for gene expression regulation, growth factors may exert multiple effects inside 
the cell.70  
The papers included in this PhD project involve data especially on PI3K, TGF-ȕ and ERĮ 
signaling and a brief introduction to these pathways in cancer is given. 
PI3K signaling 
The phosphatidyl-inositide-3-kinases (PI3Ks) are lipid kinases catalyzing phosphorylation 
of phosphatidylinositol, leading to activation of signaling pathways regulating a diverse 
panel of functions such as metabolism, vesicle trafficking, cell survival, and 
migration.91,92  
Three classes of PI3Ks (I-III) are identified, with different isoforms within each class. 
The Class I PI3Ks, the class most studied in relation to cancer, is further subdivided into 
Class IA and IB. A catalytic (PIK3CA) and a regulatory subunit (PIK3R1) compose the 
heterodimer Class IA PI3Ks, and are coupled to and activated by receptor tyrosine kinases 
(RTKs).92 The PI3K signaling pathway can be activated by binding of ligands to receptor 
tyrosine kinases such as EGFR, HER2, VEGFR, FGFR2, IGF1R and PDGFR, promoting 
tyrosine phosphorylation of an intracellular receptor domain, leading to increased affinity 
for specific intracellular proteins, such as PIK3R1. By binding of PIK3R1 to phospho-
tyrosine residues at the activated growth receptors, PIK3R1 activates PIK3CA to catalyze 
the conversion of the membrane bound phosphatidylinositol-2-phosphate (PIP2) to PIP3. 
AKT and the phosphoinositides dependent kinase 1 (PDK1) are attracted to and directly 
bind to PIP3.93 PDK1 phosphorylates the serine-threonine kinase AKT that thereby is 
activated to phosphorylate downstream signaling transducers and effectors,93 eventually 
contributing to biologic processes important to cancer initiation and progression, such as 
cell survival, proliferation, angiogenesis and metabolism (Figure 4 ).94,95  
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Figure 4. Schematic overview of PI3K signaling          
 
 
Similar effects may be seen from specific somatic mutations of receptor tyrosine kinases 
and other PI3K pathway components that render the pathway constitutively active.96,97 
PIK3CA mutations are found both in endometrioid and non-endometrioid carcinomas,72,98 
exon 20 mutations more frequent in the endometrioid cases and exon 9 mutations mainly 
seen in non-endometrioid tumors.64,99 The activating PIK3CA mutations as well as 
PIK3R1 and PIK3R2 mutations100 and PIK3CA amplifications79,101 demonstrated in 
endometrial carcinomas may contribute to sustained proliferation in this cancer type.   
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PTEN (Phosphatase and tensin homolog) contribute to PI3K pathway deactivation by 
dephosphorylating PIP3 to PIP2.102 PTEN is frequently mutated in sporadic cancer, up to 
80% reported for endometrioid endometrial carcinoma.64 Low protein expression, 
promoter hypermethylation, mutations and miRNA-21 overexpression are identified in 
endometrial cancer103-105 and are demonstrated to regulate PTEN expression and function, 
and potentially affecting to what extent PTEN further regulates PI3K signaling 
activation.102,106  
The PI3K pathway is suggested as a key target for therapy in endometrial carcinomas.30,64 
Molecular alterations potentially participating to PI3K pathway activation are 
demonstrated with varying frequency distribution between type I and II cancer (Table 1). 
Table 1. Frequency distribution of molecular alterations in Type I and Type II 
endometrial carcinoma; 1A) PI3K related alterations. 1B) Other selected molecular 
alterations.  
1A: PI3K pathways related alterations     
Target Characteristic Type I (%) Type II (%) 
ERBB2/Her2107,108 Amplification 1 17 
Overexpression 3-10 32 
EGFR108 Overexpression 46 34 
FGFR2109-111 Mutation 10-16 1 
PTEN loss of function103,104 Mut/Methyl/Low expr 83 5 
PDGFR112 Positive expression 91 73 
Phosphorylation 46 40 
AKT113 Mutation 3 0 
KRAS71,109,114,115 Mutation 11-26 2-4 
Amplification 2 10 
PIK3CA64,72,74,79,116 Mutation ~30 ~20 
Amplification 2-14 46 
PIK3R196 Mutation 20 0 
PIK3R296 Mutation 5 25 
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Table 1B: Other selected molecular alterations in endometrial carcinoma 
TP5399 Mutation ~20 ~90 
TP16 loss of function117 Loss of expression 10 45 
E-cadherin118-120 Low expression 5-50 62-87 
Microsatelite instability121,122 Present 20-45 0-5 
ERɲ,PR123 Low expression 31-44 56-69 
VEGF-A124 Overexpression 16 36 
 
TGF-ȕ 
The cytokine transforming growth factor-ȕ (TGF-ȕ) contributes to maintaining tissue 
homeostasis with regard to cellular proliferation and survival, differentiation and cell 
adhesion. The bioactive TGF-ȕ dimer brings together two receptor serine /threonine 
kinases, TGF-ȕ receptor I and II (TGFȕRI, TGFȕRII), and binding to TGFȕRII is 
followed by phosphorylation of TGFȕRI.  The activated TGFȕRI transmits the signal by 
phosphorylation of Smad transcription factors. In the nucleus, RSmad and Smad4 form a 
complex and recruits DNA-binding cofactors, and specific genes are targeted by each 
Smad4-RSmad-cofactor combination. TGF-ȕ may in this way regulate the expression of 
multiple target genes at once.125  
In cancer, the cancer cells and various cell types in the tumor microenvironment may be 
the source of TGF-ȕ. In pathologic TGF-ȕ signaling, the tumor suppressor properties 
from TGF-ȕ is lost and tumor growth, evasion of the immune system, invasion and 
metastasis are demonstrated.125 Pathologic effects from TGF-ȕ may occur by inactivating 
components crucial to the overall TGF-ȕ signaling, such as inactivating mutations in one 
of the TGF-ȕ receptors, or by alterations in downstream pathways members that inhibit 
only the tumor suppressor activity from TGF-ȕ, rendering the other TGF-ȕ functions 
active and potentially supporting the carcinogenic and tumor progressive processes.125,126  
TGF-ȕ also exerts effects on the immune system and pro-tumorigenic effects may occur if 
the immunosuppressive effects are stronger than the tumor suppressive anti-inflammatory 
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effects.125 TGF-ȕ is also an inducer of epithelial-mesenchymal transition (EMT),127 
demonstrated in various cancer types, including endometrial carcinoma.128-130  
A few studies have examined TGF-ȕ pathway related alterations in endometrial 
carcinomas. Higher TGFȕRII protein expression, Smad4 cytoplasmic protein and higher 
Smad2 and Smad 4 mRNA levels are associated with myometrial infiltration in the 
endometrioid subtype.131 Also TGFȕRII mutations are demonstrated to be associated with 
MSI and MLH1 promoter methylation and the TGFȕRII alterations are suggested being 
due to mismatch repair deficiency.132 Based on gene expression alterations related to high 
risk of recurrence, TGF-ȕ signaling has been indicated as important for aggressive 
endometrial carcinoma,130 including vascular invasion in this cancer type.133 PAI-1, a 
suggested marker for TGF-ȕ signaling,134 is associated with clinico-pathologic features of 
aggressive endometrial carcinomas and reduced survival in several studies.135-138 
Sex hormones and hormonal receptors 
Estradiol signals through the nuclear estrogen receptors (ER) Į and ȕ and G-protein 
coupled estrogen receptor, GPER. Upon binding of the bioactive form of estrogen to ERĮ, 
the activated receptor act as a transcription factor with binding to estrogen responsive 
elements (ERE) for transcription of various genes. The activity of ligand bound ERĮ is 
regulated by co-factors (suppressors and activators) and receptor phosphorylation.139 ERĮ 
is also membrane bound and may signal in a ligand-independent manner, due to 
phosphorylation of the receptor.139   
ERĮ was the first ER discovered and is per today the ER most studied in relation to 
estrogen response both in normal and cancer tissue, in comparison to ERȕ and 
GPER.140,141 ERĮ and ERȕ show different tissue distribution, also in the endometrium, 
where ERĮ is more abundant than ERȕ.139 The proliferative effect of ERĮ in the 
endometrium is counteracted by ERȕ.142   
In breast cancer, interactions between PI3K/AKT signaling and ERĮ is suggested; 
membrane bound ERĮ is phosphorylated by activated AKT and may contribute to ligand-
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independent transcriptional ERĮ activity. ERĮ is subsequently found binding to PIK3R1, 
the regulatory subunit of PI3K, participating in PI3K/AKT pathway activation.143 In 
endometrial cancer cell line studies, regulation of proliferation by ERĮ and GPER is 
demonstrated to act through Notch and PI3K/AKT signaling, respectively.144  Also, 
estradiol is demonstrated to activate PI3K/AKT signaling in ERĮ-dependent and 
independent manners in ERĮ positive and negative cell lines, respectively.145 In the 
Ishikawa endometrial cancer cell line expressing ERĮ, wild type TP53 is shown to repress 
ERĮ transcriptional activity and some TP53 mutations are linked to lack of such 
repression.146 
Progesterone signals through two different isomers of the progesterone receptor (PR), PR-
A and PR-B. PR-A is the one most studied and plays the major role in the endometrium 
where the ligand bound receptor down-regulates the actions exerted from ligand-bound 
ERĮ.141 Expression of ERĮ and PR in endometrial carcinoma is regarded a sign of 
differentiation. In endometrioid histological grade 3 tumors and in non-endometrioid 
endometrial carcinoma, low ERĮ and PR expression is common.63,147,148 A recent study 
suggests intact progesterone signaling as important for preserved immunosurveillance and 
to inhibit an invasive phenotype.149
 
Endometrial cancer biology in light of the “cancer hallmarks” 
Sustained proliferative signal and evasion from growth suppression 
For cell reproduction, where DNA is replicated and eventually split into two daughter 
cells, the cell passes through 4 stages (G1, S phase, G2 and M phase), each phase with 
specific progress in the reproductive cycle. In brief, G1 is a growth phase with protein 
synthesis required in particular for the DNA replication that takes place in the following S 
phase. In G2, the protein synthesis is again increased, related to large extent to 
microtubule formation, preparing for the coming mitosis in M phase. Cells that are not 
actively proliferating are quiescent and stably localized in G0.150 For cells to be activated 
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from G0 and enter the cell cycle, mitogens or growth factor stimulation are needed. 
Cyclins and their corresponding cyclin dependent kinases (CDK) regulate the passage 
through various stages of the cell cycle. Some of the cyclins are targets for the 
downstream signal transduction from growth factors binding to their corresponding 
receptors. Potential DNA damage during cell cycle transitions induces cellular responses 
evoked by cell cycle checkpoint signaling in G1, G2 and M checkpoints, culminating in 
cell cycle arrest if replication errors are identified. Dysfunctional checkpoint signaling 
may lead to chromosomal aberrations potentially evoking carcinogenesis.150     
Four sub-phases of the M (mitotic) phase exist (Figure 5), in addition to cytokinesis that 
parallels the telophase: In prophase, the chromatin is condensed and the centrosomes 
(consisting of centrioles and associated microtubules) are generated. The chromosomes 
are aligned in the equatorial plane in metaphase, while in anaphase the chromosomes are 
split and the microtubules are shortened. In telophase, the nuclear membranes are 
generated and chromosomes are decondensed. Cytokinesis contributes to completion of 
the cell division.  
Microtubules, the cytoskeletal tubulin polymers, are involved in a plethora of cellular 
functions and also play an important role in mitosis.151 The microtubules are dynamically 
shifted between states of elongation and shortening.152 Stathmin is demonstrated to 
destabilize microtubules potentially through two different routes: By preventing the 
assembly of tubulin and by stimulation of the microtubule catastrophe.152 The E2F family 
of transcription factors and TP53 are transcriptional regulators of Stathmin.153 Post-
translational inactivation by phosphorylation of four Stathmin phospho-sites takes place. 
This stabilizes the microtubules in the cell cycle stages before de-phosphorylation and the 
eventual shortening of microtubules in anaphase.151,153  
Mitogen signaling in cancer cells may occur through various routes:10 1. Autocrine 
proliferative signaling, where the cells produce growth factors themselves, for signaling 
through the corresponding cell surface receptors; 2. The cancer cells stimulate cells in the 
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tumor microenvironment to produce growth factors; 3. Altered levels or conformational 
changes of growth factor receptors may modify signaling in response to low levels of 
ligands or in a ligand-independent manner, respectively; 4. Constitutive activation of 
pathway members downstream of the growth receptor also promote ligand-independent 
signaling.  
Several markers of cell proliferation are present in endometrial cancer. High mitotic 
count, high expression of the tumor proliferation marker PHH3, and elevated levels of 
Ki67 expression and S-phase fraction are regarded markers for tumor cell proliferation 
and are all associated with aggressive features and reduced survival in endometrial 
carcinomas.154-157 
 
Figure 5. Overview of the cell cycle stages and details from mitosis (Adapted from 
Gray’s anatomy of the Human Body, 1918) 
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High expression of Cyclin D1, with a regulatory role in G1, is associated with aggressive 
endometrial carcinomas. CCND1 (encoding Cyclin D1) amplifications are more frequent 
in non-endometrioid endometrial carcinomas158 and a CCDN1 mutation interfering with 
the degradation of Cyclin D1 has been demonstrated in the endometrioid subtype.159 In a 
recent study on genome wide assessment of 23 serous endometrial carcinomas, 57% had 
either a mutation in the ubiquitin protein ligase gene FBXW7 or CCNE1 amplification 
(encoding cyclin E),74 both potentially contributing to increased proliferation. Cyclin E is 
an important regulator of the cell cycle progression, and is frequently up-regulated in 
cancer.76 The amount of Cyclin E is regulated by FBXW7.76 In line with these findings, 
high Cyclin E expression is associated with the proliferation marker Ki67 and features of 
aggressive endometrioid endometrial carcinomas.160   
Activating mutations of PI3K pathway members (e.g. PIK3CA, AKT) and other PI3K 
pathway activating alterations are proven tumorigenic and able to induce sustained 
proliferation despite low levels of other mitogenic stimuli.10,161 Also, activating KRAS 
mutations, as seen in endometrial carcinomas,71,162 are regarded important to sustained 
tumor cell proliferation.163 As mentioned, PI3K alterations with potentially increased 
PI3K pathway activity are frequently reported in endometrial carcinomas.64,72,79,98   
TP53, a major tumor suppressor in many cancer types, supports evasion from growth 
suppression when loss of function occur.164 TP53 is frequently altered in endometrial 
carcinomas, more often in type II carcinomas,64 and is associated with aggressive cancer 
and reduced survival.115,165 CDKNA2 (encoding p16) is regarded a tumor suppressor gene 
and plays a major regulatory role in G1/G1-S transition. CDKNA2 is frequently altered in 
endometrial carcinoma; lower p16 protein expression, promoter hypermethylation and 
deletion of CDKN2A are demonstrated,166 more frequent in non-endometrioid than 
endometrioid cancers, also reflected in reduced survival.117,167  
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Resisting cell death  
Programmed cell death by apoptosis is limiting cancer development.10 The regulators of 
apoptosis are divided into the extrinsic program (processing extracellular signals) and the 
intrinsic program (originating intracellularly) that both activate proteases that further 
participate in finalizing the apoptotic process, where eventually the cell debris is ingested 
by surrounding cells.10 In homeostasis, pro- and anti-apoptotic proteins counterbalance 
the apoptotic signals. A low expression of the anti-apoptotic marker Bcl-2 is reported in 
normal and hyperplastic endometrium and early stages of endometrial carcinoma, but 
with a higher expression in advanced cancer.168,169 An opposite expression pattern, from 
higher expression in normal endometrium to lower expression in hyperplasia and cancer, 
has been demonstrated for of the pro-apoptotic marker Bax, with highest expression in 
early stage cancer.168 The pattern of lower levels of apoptosis markers seen in advanced 
endometrial carcinoma may be due to the overall loss of cell homeostasis control in these 
cases.168 The anti-apoptosis marker survivin is demonstrated to be stronger expressed in 
cancer as compared to normal endometrium.170 The PI3K pathway, through AKT, is 
suggested to play an important role in the resistance to apoptosis.171 Recent endometrial 
cancer cell line studies have supported such a link through modulation of AKT expression 
and drugs targeting the PI3K/AKT/mTOR pathway.172-174  
Sustained tumor angiogenesis:  
Algire and colleagues proposed in 1945 that rapid tumor growth is dependent on 
development of a vascular supply.175 Judah Folkman, regarded an innovative pioneer in 
the field of angiogenesis research,176 further explored on the observations by Algire and 
laid a foundation for angiogenesis research.177-179 Folkman was the first to suggest that 
anti-angiogenesis treatment could be used in cancer therapy.178      
Like normal tissues, tumors need nutrients, oxygen, and to deposit metabolic waste. 
Vascularization is needed for a tumor to exceed the size of 1-2 mm.180 Formation of new 
vessels through vasculogenesis (generation of new endothelial cells into vascular tubes) 
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and angiogenesis (sprouting of new vessels from existing vasculature) aids to this. 
Angiogenesis is regarded to be balanced by pro- and anti-angiogenic factors (Figure 6), 
and an “angiogenic switch” to the angiogenic state, where the neovascularization is 
“turned on” is seen in development, wound healing and cancer.10  
The molecules that stimulate or inhibit angiogenesis may be ligands of endothelial 
receptors exerting the pro/anti-angiogenic effects. Vascular endothelial growth factor-A 
(VEGF-A) and trombospondin-1 (TSP-1) are examples of important pro- and anti-
angiogenic regulators, respectively. The ligand VEGF-A signals through three receptor 
tyrosine kinases (VEGFR1-3), and transcription of VEGF-A is stimulated by hypoxia and 
oncogenic signaling.181  
Figure 6. Factors contributing to the “angiogenic switch”.  
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The neovasculature in cancer is characterized by aberrant vessel morphology and 
endothelial proliferation, distorted blood flow and altered permeability.182,183 A pathologic 
tumor circulation increases the risk of tumor hypoxia that further stimulates angiogenesis. 
There is a complex interplay between tumor cells, the vasculature and other cells in the 
microenvironment surrounding the cancer cells that participate in the regulation of the 
tumor angiogenic process.184 Cells from the innate immune system are also demonstrated 
to play important roles in the cancer associated angiogenesis.185 Also, evidence for 
angiogenesis in cancer precursor lesions is demonstrated, and is suggested to be an early 
event in tumorigenesis.186 
Microvessel density (MVD; number of vessels per tissue square unit) is a measure of 
tumor vasculature but does not necessarily indicate the degree of angiogenesis or 
functionality of the present vasculature.187 MVD is therefore suggested as a measure of 
the tumor metabolic burden and not angiogenesis per se.188 High MVD is associated with 
features of aggressive endometrial carcinomas and reduced survival.124,189 Amongst 
angiogenesis related measures in endometrial carcinomas, high VEGF-A and bFGF 
protein expression is reported to be associated with clinico-pathologic features of 
aggressive disease.124,190 VEGF-A and VEGFR1 expression is also shown to be associated 
with aggressive disease and reduced survival in the endometrioid subset of endometrial 
carcinomas.191 Various measures of proliferating microvessels have been suggested as 
markers of angiogenesis. Microvessel proliferation (MVP) measured by dual 
immunostaining of Nestin/ Ki67 or Factor VIII/Ki67 for proliferating vessels 
(proliferating microvessel density; pMVD) is demonstrated to be associated with 
aggressive cancer and reduced survival.192,193 Vascular proliferation index (VPI; the ratio 
between the number of proliferating vessels and the total number of tumor microvessels) 
is suggested as a better marker for cancer neovasculature, and potentially angiogenesis.187 
In endometrial carcinomas, high VPI is associated with VEGF-A expression, tumor 
necrosis and reduced survival.124    
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Invasion and metastasis:   
The English surgeon Stephen Paget postulated “the seed and soil hypothesis” in 1889,194 
that tumor cells (denoted “seeds”) have affinity for specific tissue environments in certain 
organs (denoted “the soil”), and laid by this the foundation for a large amount of invasion 
and metastasis research that has been performed for more than a century after this 
publication.10    
Tumor cell invasion and metastasis are multistep processes immensely detrimental. The 
route to cancer dissemination is suggested by distinct steps; local infiltration, 
intravasation and transport of the cancer cells in the lymphatic or hematogenous systems, 
extravasation of cancer cells from the vessels to distant sites where micrometastases may 
form and grow to macroscopic lesions (Figure 7).195,196 Before setting off in the invasion-
metastatic cascade, it is regarded crucial that the tumor cells fulfill prerequisites such as 
the ability to detach and move from the original colony, with unlimited proliferative 
potential and a capacity to evade from destruction.197 Genes that seem to support the 
metastasis to specific organs have been identified, although their exact functional 
mechanisms are more difficult to reveal.198 The underlying effectors in the invasion-
metastasis cascade is suggested to be classified as metastasis initiating, metastasis 
progressing  and metastasis virulent.198 Metastasis initiating genes generate a supportive 
environment that facilitates tumor infiltration to surrounding tissue. A tumor environment 
that facilitates cancer invasion is considered important to the invasive process.10 
Membrane bound proteases as MMPs and ADAMs may contribute to this, by remodeling 
the tissue in manners that ease the movement of cancer cells in the tumor tissue and by 
regulating the availability of extracellular growth factors.199 In endometrial carcinoma, 
various MMPs are associated with features of aggressive disease and reduced survival.200-
202 MMP2, -3 and -9 is demonstrated associated with vascular invasion and myometrial 
infiltration.133,201 Metastasis initiating genes may further promote angiogenesis, evasion 
from immune destruction and epithelial-mesenchymal transition (EMT), with all its 
implications to the cancer metastatic processes.198 
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Epithelial-mesenchymal transition: A conversion from an epithelial to a mesenchymal-
like phenotype is regarded important for normal development and wound healing.203,204 
The ability of cancer cells to reversibly alter their phenotype in response to external 
signals is also denoted “plasticity”,205 and is regarded important for the metastatic process 
in general and for EMT in particular.206,207 When pathologically activated, EMT may have 
significant impact on cancer invasion, apoptosis resistance, drug resistance and evasion 
from immune surveillance.127 Epithelial cells that enter the EMT program lose their 
adherence to neighboring cells and the apicobasal cell polarity and also acquire migratory 
and invasive properties.127 Reduced expression of E-cadherin, a protein with cell adhesive 
properties, is regarded one of the “EMT hallmarks”.10,127  
Figure 7. An overview of the invasion-metastasis cascade (adapted from 195). In the 
patient figure, turquoise dots denote metastatic tumors (lung and lymph nodes).  
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Low expression of membranous E-cadherin and ȕ-catenin, molecules implicated in cell-
cell adhesion, is demonstrated in endometrial carcinoma and associated with aggressive 
clinico-pathologic phenotype and reduced survival.120,208-210 N- and P-cadherin are also 
regarded as EMT markers,127,211 and are together with the cell adhesion marker catenin 
p120 demonstrated to be altered in aggressive endometrial cancer.120,209  
The E-cadherin repressors Snail, Slug, ZEB 1 and 2 and KLF8 are transcription factors 
that bind to the E-cadherin promoter and are regarded EMT inducers together with Twist, 
Goosecoid and FOXC2 that indirectly repress the E-cadherin expression.10,127 A 
cooperation between EMT inducing transcription factors is suggested, and both spatial 
and temporal factors seems to be included in this complex interplay.127 High Snail and 
Twist expression is associated with low E-cadherin in endometrial cancer.212-215 One study 
suggested Snail upregulation linked to activation of EGFR.216 L1CAM is associated with 
aggressive endometrial carcinomas and is suggested as an EMT marker in this cancer 
type. There is support for L1CAM upregulation being induced by TGF- ȕ through Slug.213 
Several signaling pathways are suggested to trigger EMT, the TGF-ȕ signaling being one 
potent inducer.10,127,217 TGF-ȕ/Smad mediated HMGA2 expression promotes transcription 
of Twist, Slug and Snail and subsequent E-cadherin repression.218 HMGA2 is also found 
higher expressed in serous compared to endometrioid endometrial carcinomas.219 A study 
of gene expression alterations related to recurrent endometrial carcinomas identified TGF-
ȕ signaling in tumors that recurred.130 Functional cell line experiments confirmed an 
important role for TGF-ȕ in the invasive phenotype. Also, TGF-ȕ is associated with 
vascular invasion and EMT in endometrial cancer.129,133 A recent and thorough 
exploration of EMT drivers in FIGO stage I endometrioid endometrial carcinomas 
revealed that E-cadherin repressors as Snail, Slug, Zeb1, Twist and HMGA2 was stronger 
expressed in endometrial carcinoma than normal endometrial tissue, and tumors with deep 
myometrial infiltration had higher expression of Slug, Zeb1 and HMGA2 compared to 
samples with none or superficial infiltration.214 This study suggested the MAPK/ERK 
pathway as an important driver in EMT in early endometrioid endometrial carcinomas. 
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Micro-RNAs (miRNAs) are promoted as important contributors to EMT in endometrial 
cancer.89,129 
Angiogenesis and vascular invasion is considered to be part of the metastasis initiating 
process. Vascular invasion is associated with clinico-pathologic features of aggressive 
endometrial cancer.155,220 Absent expression of CD44v6, an isoform of the cell-cell 
adhesion molecule CD44 is associated with deeply infiltrating endometrial carcinomas 
and vascular invasion.221 A study exploring on gene expression alterations related to 
vascular invasion in endometrial cancer identified VEGF and TGF-ȕ as potentially related 
to vascular invasion and a 18-gene expression signature associated with vascular invasion 
was identified.133 ANGPTL4 was one of the genes in the signature and was more highly 
expressed in aggressive tumors and also associated with vascular invasion. ANGPTL4 is 
previously linked to TGF-ȕ signaling and suggested to facilitate trans-endothelial passage 
of tumor cells.222   
Genes supporting metastasis progression promotes extravasation and survival of the 
cancer cells outside of their original environment.198 Cancer cells that have entered the 
circulation may extravasate and infiltrate distant organs. It has been demonstrated that 
specific vascular beds have distinct molecular expression and tumor cells expressing the 
corresponding receptor may become entrapped in this capillary bed, as the step before 
extravasation.196 Extravasation through capillary barriers further require specific 
molecular tumor cell characteristics that enable the cells for this function.198 The 
endothelial cells in capillaries of some organs are fenestrated, making the passage of 
tumor cells more likely to occur. For extravasation to other organs with a tight endothelial 
layer, organ specific mediators are suggested for extravasation.198 ANGPTL4 is pointed to 
as a specific mediator of lung metastasis,198 and also demonstrated higher levels in 
aggressive endometrial cancer.133     
For colonization to occur, a process where the disseminated cancer cells reside in their 
new microenvironment and grow into macrometastases, adaptation of the tumor cells to 
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this environment is required.10 To succeed in the metastatic colonization, the cancer cells 
need to overcome microenvironmental hostility and activate self-renewal pathways.223 
Specific cancer cell gene expression is suggested to direct organ specific tropism; One 
example is the expression of IL-11 that facilitates breast cancer bone metastases.223 A 
“receptive” environment at the future metastatic location, set up before the colonization of 
tumor cells, is denoted the pre-metastatic niche.224 There is evidence that cancer-specific 
factors released from the primary tumor promotes changes in the future metastatic 
microenvironment before the tumor cells arrive to this location. Also, bone marrow cells 
migrate to the pre-metastatic niche in response to the systemically released factors, 
facilitating the environment for the cancer cells to “thrive”.225,226 Conversely, the presence 
of “resistant niches” has recently been described.227 
The EMT-inducers Snail, Zeb1 and Twist promote self-renewal properties in cancer cells, 
a characteristic that promotes the metastatic colonization.127 The gene and protein 
expression of organ specific metastases is not elucidated to large extent in endometrial 
carcinomas. However, higher frequency of KRAS amplification and low GPER 
expression is demonstrated in both lymph node metastases and distant metastases 
compared to primary endometrial cancer.71,228   
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1.4 Clinical picture and diagnosis  
Clinical aspects 
Primary endometrial carcinoma is located in the endometrium of the uterus. Bleeding 
from tumor may pass through the vagina, and abnormal bleeding is therefore a common 
early symptom.28 Women in the pre- and perimenopausal periods will relatively 
frequently experience irregular bleeding,229 for the majority of women caused by 
hormonal imbalance.230 In contrast, a postmenopausal bleeding is an alarming sign for 
most women, and those experiencing this more urgently seek immediate medical 
examination to diagnose the cause of bleeding. The overall risk of endometrial cancer for 
a woman with postmenopausal vaginal bleeding is 5-10%, the risk increasing with 
increasing age and other additional risk factors.231 
The spread of cancer occurs through three routes:9  
1. Direct spread occurs by the direct seeding of tumor cells from the tumor to nearby 
areas. In endometrial cancer, direct spread may occur to the peritoneal cavity by 
tumor extending through the myometrium and uterine serosa, to the vagina through 
spread downwards from the uterine cavity or cervix, or growth may extend directly 
into the para-cervical area. 
2. Lymphatic spread happens by transport through lymphatic vessels located at the 
tumor margins.232 The pattern of metastatic involvement of lymph nodes follow the 
natural routes of lymphatic drainage, but “skip metastases” may occur when pelvic 
local lymph nodes are being bypassed in the metastatic spread,9 as also observed 
with sole paraaortic lymph node metastases in endometrial carcinoma.233,234  
3. Hematogenous spread occurs by tumor cell invasion mainly to veins. Tumor cells 
follow the blood flow draining the area where the tumor is localized, and reside in 
capillary beds encountered.9 This spread pattern therefore frequently involves the 
liver and lungs. In endometrial cancer, distant metastases, in addition to distant 
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lymph node metastases, are found most frequent in the lungs, but also in liver, 
bone and brain.234 
The diagnostic measures taken when suspecting endometrial cancer are primarily used to 
establish an accurate diagnosis of cancer, or exclude such one. Secondarily, having 
demonstrated the cancer diagnosis, the next critical step is to assess the extent of the 
disease to tailor surgical and systemic therapies. The goal is to identify cancer patient 
subgroups that are at higher risk for developing recurrence and therefore in need of more 
extensive surgical and systemic therapy, including adjuvant treatment. Although not yet 
implemented in clinical practice in a standardized manner, biomarkers such as hormone 
receptor status, may further identify high risk patients and represent a potential target for 
therapy, also indicating whether a patient is more likely to respond to the alternative 
therapies in the adjuvant and metastatic settings.30 
 
Diagnosis 
Abnormal vaginal bleeding often requires examination of endometrial cytology or 
biopsy.235,236 If malignancy is suspected or the diagnosis based on a cytological 
examination is inconclusive, an endometrium biopsy is crucial. The majority of 
endometrial cancer patients are diagnosed by such a biopsy; out-patient endometrium 
biopsies by Pipelle de Cornier curettage or a classic fractional dilatation and curettage 
(D&C) with sampling separately from the uterine corpus and cervix.28,237 The biopsy is 
required to confirm a diagnosis of cancer and in particular to reveal preliminary 
histopathologic diagnosis. Both the Pipelle curettage and D&C are considered equally 
sensitive and specific for diagnosing endometrial cancer,238-240 although caution should be 
taken if negative or inconclusive cancer diagnosis  by Pipelle, as it is demonstrated that 
Pipelle more often than D&C provide insufficient amount of tissue for proper 
histopathologic diagnosis.241,242 Correct preoperative histopathologic diagnosis is 
important to guide the surgical treatment planning; Preoperative high-risk cases are 
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recommended referred to tertiary centers and operated by gynecologic oncologists with 
complete pelvic and para-aortal lymphadenectomy. Other patients may be safely operated 
at secondary centers.237,243 More wide-ranging surgery by radical hysterectomy may be 
planned if disease extends into the cervical stroma.244,245 
Imaging 
Transvaginal sonography (TVS) is a diagnostic tool recommended in the evaluation of 
abnormal bleeding.235,236 Assessing the endometrium of premenopausal women might be 
difficult, as the cyclic hormonal changes influence the endometrial thickness. The risk of 
endometrial cancer is reported to be only 1-2.3% if a postmenopausal endometrium is 
measured by TVS to be <4-5mm, including both endometrial layers.246,247 This cut-off has 
been commonly used in the clinical setting when assessing risk of endometrial cancer 
based on findings from TVS.236,248 The cut-off might need to be adjusted, depending on 
whether irregular bleeding is present or not. The authors of a recent meta-analysis 
recommend a cut-off for the endometrial thickness of < 3mm to exclude endometrial 
cancer in postmenopausal bleeding.248   
TVS has been considered a potential tool to determine depth of myometrial infiltration 
and cervical stroma infiltration pre-operatively; the sensitivity for detecting myometrial 
infiltration  50% range from 62-78% and specificity from 81-94%.249-252 For detection of 
cervical stroma invasion, sensitivity is reported to be 77-86% and specificity 85-
99%.251,252  Three-dimensional (3D) ultrasound is also suggested as a potential measure 
for improved assessment of myometrial infiltration.253  
Examination of the chest and abdomen/pelvis for potential metastatic lesions is part of the 
pre-operative examination of endometrial cancer. Chest X-ray or computed tomography 
(CT) and abdominal/pelvic CT or magnetic resonance imaging (MRI) detect metastases in 
the depicted areas. Contrast enhanced MRI has been the preferred imaging method in 
preoperative staging the last years, and has demonstrated to be superior to CT and TVS in 
identifying deep myometrial invasion and cervical involvement.254,255 The ability to detect 
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cervical invasion by MRI exceeds that of histologic evaluation by endocervical curettage 
as part of the D&C.256 PET-CT is more sensitive for detecting metastatic disease, but the 
clinical benefit is unsettled and thus not yet part of standard preoperative examinations for 
endometrial carcinomas.30  
Other potential diagnostic tools 
As specific changes may occur in biological fluids and tissues before development of 
cancer symptoms, such alterations can in principal be used as markers for early 
diagnosis.257 No serum or urine marker is presently available for routine clinical 
application to handle endometrial cancer patients today. CA125,258 GDF15,259 prolactin260 
and HE4, alone or in combination with CA125,261 are amongst the serum/plasma markers 
shown to predict prognosis in endometrial cancer. The utility for these markers in early 
diagnosis and to individualize therapy for endometrial cancer patients remains to be 
further studied in larger and prospective studies.  
Per today, screening for endometrial carcinoma in the general population by ultrasound, 
pipelle or serum markers is not recommended.262,263 
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1.5 Histopathology  
The gross appearance of endometrial carcinomas may be one or more polypoid tumors, or 
the growth can be seen as a more diffuse expansion in the uterine cavity. The Pathology 
Report Guidelines by the Norwegian Society of Pathology (2012) recommends reporting 
on histologic subtype, histologic grade, vascular invasion, depth of myometrial infiltration 
and presence of cervical stroma infiltration, lymph node involvement and other 
extrauterine disease (surgical staging) as part of the routine histopathological reports for 
endometrial carcinomas.264 
The histologic subtype of endometrial carcinomas is defined by the cell type(s) that 
constitute the specific tumor and is regarded to be important with respect to determine the 
clinical course of uterine cancers.67 By histologic examination, 85-90% of endometrial 
carcinomas are endometrioid adenocarcinomas with a glandular pattern similar to normal 
endometrial epithelium.28,64 These cancers also comprise adenocarcinomas with 
squamous, secretory or ciliated differentiation. Endometrioid tumors are graded based on 
the amount of solid growth of the glandular component, adjusted by nuclear features 
(FIGO grading):9,265  
Histologic Grade 1: Adenocarcinoma with easily recognizable glandular pattern. Less 
than 5% solid growth.  
Histologic Grade 2: Well-formed glands with interspersed solid sheets of malignant cells. 
Less than 50% solid growth. 
Histologic Grade 3: Solid sheets of cells with barely recognizable glands. More nuclear 
atypia and mitotic activity. Solid growth > 50%.  
Severe nuclear atypia raises the grade by one. 
An alternative grading system has been proposed, where high grade cases included  2 of 
the following architectural features: 1) > 50% solid growth, 2) a growth pattern of diffuse 
infiltration, 3) tumor cell necrosis, as defined by areas of necrotic tumor adjacent to viable 
tumor tissue.266  
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The histologic subtypes serous, clear cell and undifferentiated carcinomas are included in 
the non-endometrioid (NE) endometrial carcinomas.265 Serous carcinoma is the most 
frequent subtype amongst these cancers (3-10% of endometrial carcinomas).64 
Carcinosarcoma, also denoted Malignant Mixed Müllerian Tumor (MMMT), is a separate 
entity within the endometrial carcinomas. This histologic subtype is comprised by both 
epithelial and stromal components. Recent clinico-pathologic, immunohistochemical and 
genetic studies have provided evidence that carcinosarcomas most likely represent 
carcinomas with a mesenchymal component as a consequence of metaplasia and /or tumor 
progression.267,268 Carcinosarcomas are today treated like endometrial carcinomas and are 
in studies often included in the non-endometrioid endometrial carcinomas.64 All non-
endometrioid carcinomas are classified as histologic grade 3 per definition and further 
grading is not performed.265 
A proportion of endometrial carcinomas area denoted “ambiguous”, with morphologic 
features overlapping with the known histologic subtypes, complicates the histologic 
diagnosis.269-271 The clinical relevance to a more precise diagnosis is not yet clear.271 
Immunohistochemistry may be an aid to the histologic diagnosis and TP53 
immunostaining is suggested as relevant to differentiate for example high grade 
endometrioid and serous carcinomas, also with add of PTEN and PR.271,272    
 
Myometrial infiltration (Figure 8A) is recommended to be measured in mm. For cases 
with myometrial infiltration, the fraction of infiltration depth (mm) related to total 
myometrial thickness (mm) is reported.264 As the endo-myometrial junction is not a 
straight line, the endometrial “tongues” of varying length towards the myometrium may 
mimic myometrial invasion and contribute to myometrial invasion being overdiagnosed 
(Figure 8B).67,273 Determination of depth of myometrial infiltration is important for the 
distinction into FIGO stage IA vesus IB i.e. <50% versus >50% infiltration of the 
myometrial wall (Table 2).  
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Figure 8. A) Cancer infiltration of the myometrium. B) Endometrial cancer confined to 
the endometrium (Stage IA) resembling myometrial invasion by its irregular intra-
endometrial growth. Reprint with permission, from J Prat 2004.67  
                     
 
Cervical infiltration was previously classified in the FIGO surgical staging criteria as 
none infiltration, epithelial involvement or stromal infiltration.274 In the FIGO stage 
definitions revised  in 2009, only cervical stromal infiltration is classified and treated as 
FIGO stage II disease.275 Cervical involvement may occur from direct surface or stromal 
extension of the tumor growth from the uterine corpus, but may also be due to lymphatic 
spread67  and has also been suggested as implantation from the diagnostic curettage 
procedure.276,277 In the study by Jordan et al., it was denoted that only small areas of the 
cervical circumference was affected by tumor.277 This points to the importance of 
appropriate sampling in the D&C procedure, and raises the awareness of interpreting the 
D&C histology report with care, regarding the diagnosis of cervical involvement.      
 
A B 
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Vascular invasion 
Vascular invasion is reported to contribute independent prognostic information, and is 
thus recommended to be included in standard histopathology reports for endometrial 
carcinomas.265 Perivascular lymphocyte infiltrates may help in identifying vessels with 
vascular invasion, while retraction artifacts around a tumor gland might be mistaken as 
vascular invasion.67 Staining of endothelial cells with Factor VIII or CD31 facilitates 
recognition of vascular invasion, and blood vascular invasion may be separated from 
lymph vascular invasion by concurrent staining with D2-40 and CD31 antibodies.278,279  
 
1.6 Therapy  
The therapeutic aim for cancer has traditionally been to “cure” the patient from disease by 
eradicating the primary tumor and any micro-/macro metastases. This is in contrast to 
how we aim to treat various other diseases, e.g. hypertension and rheumatic diseases, 
where the overall aim is to relieve symptoms and prevent secondary harmful effects of the 
disease. Nearly 20 years ago, a change in the goal of cancer therapy was suggested, 
moving from a “killing paradigm” to a “regulatory model” where residual disease was 
controlled by regulation of pathways contributing to the deregulated growth.280-282 The 
“regulatory model” was somehow the initial step towards the “targeted therapy” and 
“personalized medicine” concepts that both the scientific and clinical societies today 
embrace. The aim is to improve survival and quality of post-therapy life. The means are 
to administer appropriate therapy at the right time to the right patient groups.   
Many treatment regimens in clinical use today (2013) are still based on the “killing 
paradigm”, removing tumor surgically where possible and treating micro and macro 
metastases with systemic therapies and radiation.  
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In the following, an overview of evidence for current standard care will be given. The 
status for clinical implementation of the more novel and “targeted therapies” in 
endometrial carcinoma is presented in chapter 1.8.  
Primary surgical treatment 
Table 2. Surgical tumor staging accordingly the International Federation of Obstetrics 
and Gynecology (FIGO); 1988- and 2009 classifications. 
Stage FIGO1988274 FIGO2009275
I IA: Tumor limited to endometrium IA: Tumor with no or <50% myometrial
Infiltration 
IB: Myometrial infiltration < 50% IB: Myometrial infiltration > 50% 
  IC: Myometrial infiltration > 50%   
II IIA: Endocervical glandular involvement, II: Tumor invades cervical stroma, but 
Only does not extend beyond the uterus 
  IIB: Cervical stromal invasion   
III IIIA: Tumor invades serosa and/or adnexa  IIIA: Tumor invades the serosa of the  
with/without positive peritoneal cytology corpus uteri and/or adnexa 
IIIB: Vaginal metastases 
IIIB: Vaginal and/or parametrial 
involvement 
IIIC: Metastases to pelvic and/or para- IIIC1: Metastases to pelvic lymph nodes  
aortic lymph nodes IIIC2: Metastases to para-aortic lymph 
nodes with/without positive pelvic lymph 
    Nodes 
IV IVA: Tumor invasion of bladder and/or  IVA: Tumor invasion of bladder and/or  
bowel mucosa bowel mucosa 
IVB: Distant metastases, including intra- IVB: Distant metastases, including intra- 
abdominal metastases and/or inguinal 
lymph 
abdominal metastases and/or inguinal 
lymph 
  node metastases node metastases 
FIGO stage I: Hysterectomy and bilateral salpingo-oophorectomy (BSO) is the 
cornerstone in primary treatment of endometrial carcinomas.283 The rationale for this 
therapy in early stage cases is to mechanically remove all tumor cells present, with 
curative intent. In young women with superficially growing lower grade endometrioid 
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tumors (FIGO stage IA), the ovaries may be preserved, although considered to have a 
potential risk for leaving behind malignant ovarian tumors from endometrial cancer 
spread or synchronous ovarian cancer.283,284   
For carcinosarcomas, clear cell and serous endometrial carcinomas, omentectomy has 
been recommended due to the increased risk of intra-abdominal spread of these cancer 
subtypes similar to what is seen for serous ovarian cancer.285,286 Although the gross 
inspection peri-operatively is advocated and normal macroscopic appearance predicts no 
omentum metastases (negative predictive value =0.94, CI=0.81-0.99),287 omentectomy is 
frequently carried out as part of the primary surgical treatment to this group of 
endometrial cancer patients.288 As the morbidity associated with omentectomy is 
considered low, this may favor the procedure in clinical practice.288 
Lymphadenectomy: As the surgical FIGO 2009 staging classification relies on both pelvic 
and para-aortic lymph node status (metastatic or not),275 both pelvic and para-aortic 
lymphadenectomy is recommended for complete staging.  
The role of lymphadenectomy in primary surgical treatment of endometrial cancer has 
been heavily debated. The key controversies relate to finding the right balance between 
the potential therapeutic effects from surgery, directly or indirectly by identification of 
risk groups for adjuvant therapy, and the side-effects from the procedures.289,290 
Retrospective observational studies have shown a positive survival effect of 
lymphadenectomy in intermediate and high risk cases (HR for disease specific/overall 
survival=0.25-0.65),291-294 while two large prospective randomized studies did not 
demonstrate any such effect.295,296 Clinical practice varies from selective 
lymphadenectomy in patients with increased risk of nodal metastases to mandatory pelvic 
and para-aortic lymphadenectomy, independent of preoperative diagnosis as long as the 
patient’s co-morbidities do not prevent such surgery.283  
It has also been suggested that designing a prospective, randomized trial resolving the 
lymphadenectomy-question may not be ethical justifiable, as such a study would require 
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that some high-risk patients would not be given adjuvant therapy.289 An alternative 
approach is to develop methods for more accurate prediction of negative lymph node 
status amongst patients with tumors confined to uterus that would not benefit from 
lymphadenectomy297,298 
FIGO stage II: Extended or radical hysterectomy including excision of para-cervical and 
parametrial structures and a larger vaginal cuff is recommended to patients with cervical 
epithelial or stromal involvement.288 Although not justified by randomized trials, several 
retrospective studies demonstrate a significant survival benefit from radical hysterectomy 
and BSO with or without lymphadenectomy, compared to simple hysterectomy 
alone.244,299-301 Radical hysterectomy is associated with more intra- and postoperative 
complications,302 and should therefore be designated to the appropriate patient subgroup. 
FIGO stage III/IV: Patients with primary advanced disease may benefit from delbulking 
tumor burden. A meta-analysis of 14 retrospective studies (672 patients with advanced or 
recurrent endometrial cancer) indicated that complete cytoreduction (< 2cm tumor left) 
improves overall survival time.303 
 
Adjuvant treatment 
Adjuvant therapy is given as supplementary treatment after primary surgery. The main 
rationale for administering adjuvant therapy after macroscopic tumor is considered 
surgically removed, is to eradicate potential microscopic residual disease not removed at 
primary surgery, aiming to improve overall survival and disease-related symptoms. 
Adjuvant therapy is in clinical practice given to patients at a certain risk of disease 
relapse, despite being radically operated. 
Risk-stratifying algorithms for classifying endometrial carcinoma patients according to 
their risk of recurrence after treatment for localized disease have been suggested to guide 
the adjuvant therapy;237,304 the guidelines per April 2013 in Norway are presented in 
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Table 3. Histologic type, histologic grade and depth of myometrial infiltration are 
included in the risk stratification.237 Lymph gland assessment and DNA ploidy 
investigation are suggested to improve the risk stratification within the intermediate risk 
group. 
 
Table 3. Risk of recurrence algorithm including histologic type, histologic grade and 
depth of myometrial infiltration (from Norwegian Gynecologic Oncology Guidelines 
2009) 
NORWAY (2009) FIGO IA/IB FIGO IC 
Endometrioid Grade 1 or 2 Low risk Intermediate risk 
Endometrioid Grade 3 Intermediate risk High risk 
Non-endometrioid histologic type High risk High risk 
 
The National Comprehensive Cancer Network clinical practice guidelines include age 
>60 years, lymphovascular space invasion, tumor size, and lower uterine involvement in 
addition to histologic grade and myometrial infiltration to guide selection for adjuvant 
therapy.304 
Women of age <60 years, FIGO I surgically staged with endometrioid histology, 
histologic grade 1 or 2, myometrial infiltration <50%, and no lymph vascular space 
invasion, are expected to have low-risk of metastatic disease and no adjuvant therapy is 
recommended.237,290,304  
Adjuvant radiation therapy  
Radiation therapy may be administered internally as vaginal brachytherapy or externally, 
directing radiation to the pelvis, para-aortic or whole abdominal areas. Four randomized 
controlled trials have demonstrated significantly reduced risk of local recurrence after 
adjuvant external radiotherapy for FIGO stage I and II cases, but no survival benefit.305-309 
Based on subgroup analyses though, a potential survival benefit amongst FIGO stage IC 
59

patients is possible (registry based study).310 Meta-analyses have supported an effect on 
survival for patients with stage IC, grade 3 tumors.311,312 In order to see if vaginal 
radiotherapy was as effective as external radiation for vaginal control, a randomized trial 
of 427 stage I or IIA patients compared vaginal and external radiotherapy. It was 
demonstrated that vaginal brachytherapy was effective in ensuring vaginal control with no 
significant differences in local recurrences or survival for the two treatment 
alternatives.309 The frequencies of gastrointestinal side effects were significantly lower for 
patients who received vaginal brachytherapy.313 In view of these results, some advocate 
that vaginal brachytherapy should be the standard adjuvant treatment to patients regarded 
of intermediate risk for metastatic disease.314 Adjuvant external radiation therapy should 
be chosen for patient subgroups with high risk of recurrences, as the benefits from such 
therapy outweigh the risk of treatment associated toxicities.314 
Both internationally and in Norway, the use of adjuvant radiation therapy in clinical 
practice has declined, accompanying the increase in surgical staging.315-318  
Adjuvant chemotherapy   
There is a need for effective systemic therapies as patients with uterine confined tumors 
recur at a relatively high frequency (up to ~30%) after receiving adjuvant pelvic radiation 
therapy.319 Systemic therapies have advantages above radiotherapy, potentially attacking 
tumor cells also outside of irradiated area.  
The use of adjuvant chemotherapy has been increasing in Norway.317 Platinum based 
chemotherapy, anthracyclines (e.g. doxorubicin, epirubicin) and paclitaxel are the classes 
of drugs most frequently used, both in the adjuvant and metastatic settings.320,321 A recent 
Cochrane review compared the effect of adjuvant chemotherapy in addition to surgery 
with or without radiation, and concludes that chemotherapy is likely to improve overall 
survival (HR=0.74, 95% CI: 0.62-0.89) and limits the risk of extra-pelvic recurrences 
(HR=0.79, 95% CI: 0.68-0.92). The platinum based therapy is assumed to be a main 
effector.320   
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Merged data from two randomized trials demonstrated significantly increased 5-year 
progression-free and disease specific survival when adding chemotherapy to external 
radiation therapy (72%-79% and 79-88%, respectively).322  
There are ongoing randomized clinical trials evaluating the effect of radio- and 
chemotherapy and combinations of these for patients with localized and advanced disease 
(www.clinicatrials.gov, September 2012). These studies may also clarify unresolved 
issues related to such combination therapy; the patient subgroups benefitting most from 
this therapy, optimal treatment algorithms and selection of patients for external or vaginal 
radiotherapy.314 
 
Adjuvant hormonal therapy 
One Cochrane review on adjuvant progestagens in endometrial cancer included studies of 
stage I cases as well as primary advanced endometrial cancer.323 Progestagens was not 
supported as adjuvant therapy. However, the tumor progesterone receptor status was not 
assessed in any of the studies, likely to be of importance when evaluating the effect of a 
ligand binding to this receptor.  
Applying adjuvant therapy is a lot about risk-definitions and ensuring that the benefits 
from the therapy outweigh the adverse effect, leaving the patient with the optimal quality 
of life, regarded the circumstances.320 
 
Treatment of primary advanced and recurrent disease  
The choice of therapy for women with recurrent and advanced primary disease depends 
on various factors, such as the localization(s) of the tumors(s), previous treatment and the 
general health of the woman. The clinical picture at recurrence may range from a solitary 
vaginal recurrence with a potential for curative treatment, to widespread systemic disease. 
61

Surgery, radiation therapy and systemic therapy (chemotherapy and hormonal therapy) 
are thus all alternative therapies in the recurrent setting.  
Postoperative chemotherapy (dual regimen) to women with FIGO stage III or IV cancer, 
surgically debulked to residual tumor < 2 cm, is demonstrated to have better effect than 
whole abdominal radiation with respect to progression-free and overall survival, HR=0.71 
(95% CI: 0.55-0.91),324 and is today the first choice of postoperative treatment for women 
with primary advanced disease.283 A rationale for combined chemotherapy and radiation 
has also been demonstrated,325 and is frequently used in clinical practice, although the 
best regimen for such combined therapy is probably yet to be determined.283  
No single chemotherapeutic drug is demonstrated to have clear beneficial effect in 
primary advanced or recurrent endometrial cancer. Doxorubicin and Cisplatin are 
regarded the most active drugs in mono-therapy; response rates range from 17% to 25% 
for Doxorubicin.326-329 Combinations of chemotherapy are demonstrated to have better 
effects on disease free survival when compared to less intensive therapy regimens, 
although increasing toxicity is also seen with the more intense treatment regimens.330 
Combinations of Doxorubicin and Paclitaxel or Cisplatin in the recurrent setting 
demonstrated similar response rates and survival.326,331 
Vaginal recurrences are primarily treated with radiation therapy in patients with no such 
previous treatment.283 Isolated vaginal recurrences in surgically treated endometrial 
carcinoma stage I cases should be evaluated for surgical therapy and have also been 
successfully cured with combined whole pelvic and vaginal radiation therapy, with 5- 
year overall survival after diagnosis of the recurrence of 75%.332 
As radiation therapy is not given to a previous irradiated field, radical surgery is the only 
curative option for women who received radiation therapy as adjuvant therapy.283,288 
Surgery in such area presents challenges with respect to poor wound healing, increased 
risk of infections, and secondary hemorrhage and difficult hemostasis,333 leading to 
increased risk of surgical complications and long-term co-morbidities.288 However, a 
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retrospective study of 61 endometrial cancer patients demonstrated that complete 
cytoreduction of pelvic recurrences with no residual gross disease was beneficial based on 
an observed longer post-recurrence survival than for patients with gross residual tumors 
(39 months versus 13.5 months, respectively, P<0.0005).334 The not randomized design 
for the study should call for caution in the conclusions though.  
The effect of various hormonal therapies (e.g. progestagens and anti-estrogenic drugs) to 
advanced and recurrent endometrial carcinoma is evaluated in several studies, reporting 
varying effects, from no effects to response rates up to 30%, with median overall survival 
7-11 months.335,336 A recent Cochrane review evaluating the effect of hormonal therapy in 
advanced and recurrent endometrial carcinomas states that the evidence from randomized 
controlled trials per 2010 is inadequate to conclude in this question. Several of the studies 
included have reported response to hormonal treatment, independent of the tumor 
expression of progesterone and/or estrogen receptors.336 In studies evaluating response 
according to hormone receptor status, patients with receptor positive primary tumors have 
been reported to respond better than patients with receptor negative tumors.337,338  
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1.7 Biomarkers in endometrial cancer  
The National Institute of Health Biomarkers Definitions Working Group defined a 
biomarker as a “Characteristic that is objectively measured and evaluated as an indicator 
of normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”.339 
Cancer biomarkers are ideally used to aid in decisions related to diagnosis and treatment: 
“Who to treat” (prognostic markers), “How to treat” (markers predicting therapy 
response); and “How much to treat” (pharmacodynamic markers), as illustrated in a 
hierarchy in Figure 9. 
Figure 9. Types of cancer biomarkers and their clinical application for therapy decisions. 
“+” denotes “marker positive” and implies next level biomarker assessment.   
             
64

A prognostic biomarker identifies groups amongst cancer patients that are likely to 
experience recurrence and poor outcome. Such patient groups may potentially benefit 
from more extensive therapy to reduce the risk of recurrent disease and thereby improve 
outcome/survival if the treatment is effective. Biomarkers that predict therapy response to 
a specific therapy are named predictive biomarkers. When the appropriate drug for the 
appropriate patient is selected, pharmacodynamic biomarkers may further assist in 
selecting the optimal dose of a specific drug to further improve the benefit from the 
treatment and reducing side effects.  
From the biomarker definition given by the NIH Biomarkers Definitions Working Group, 
both clinical, histopathologic, imaging and molecular data might be relevant as 
biomarkers in cancer.339    
 
Prognostic biomarkers  
Clinical factors  
Nulliparity is associated with reduced survival, also in multivariate analyses adjusting for 
clinico-pathologic variables (HR 1.5-2.8).340,341 High age is also suggested as an 
independent prognostic marker in endometrial carcinomas,165,342 and high histologic grade 
and non-endometrioid histologic subtype are more frequently occurring in patients of 
higher age. This, together with the relative decrease in complete surgical staging as well 
as less aggressive therapy, both in the adjuvant and metastatic setting,234 may contribute 
to explain the prognostic impact of age.   
Histopathologic factors 
Non-endometrioid endometrial carcinomas are associated with poor survival. Patients 
with these tumors experience 35-45% 5-year survival, compared to 75-83% survival in 
patients with endometrioid subtype.28,29,234,343 The 5-year survival is also decreasing with 
increasing histologic grade in endometrioid cases, and is in one study reported to be 98% 
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for grade 1 cases, 89% for grade 2 cases and 67% for grade 3 cases.155 High histologic 
grade is associated with reduced survival, also when adjusting for other clinico-pathologic 
variables.234,344-346  
Deep myometrial cancer infiltration (>50%) is associated with poor survival 
independently of FIGO stage and histologic subtype, and is also associated with lymph 
node metastasis.155,342,347,348 
Vascular invasion is a strong prognostic marker in endometrial cancer.155,220 Also, 
separate registration of lymph vascular invasion or blood vessel invasion (Figure 10) has 
demonstrated independent survival impact for each of these factors in multivariate 
survival analyses, as well as the strongest impact from the latter279,349 
Figure 10. Blood vascular invasion (CD31 positive vascular cells surrounding tumor 
cells, A-B) and lymph vascular invasion (D2-40 positive vascular cells surrounding tumor 
cells, C-D). Reprint with permission, from Mannelqvist et al 2009.279 
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High mitotic count, a measure of increased tumor cell proliferation, is associated with 
prognosis in endometrial cancer.155 Presence of tumor infiltrating lymphocytes are shown 
to be associated with improved overall survival, independent of age, FIGO stage, 
myometrial infiltration, histologic subtype and grade suggesting the importance of 
immunologic reactions to tumor.350   
FIGO stage is by far the strongest prognostic marker in endometrial carcinoma.234 The 
stages are defined by histopathologic assessment of depth of myometrial infiltration, 
presence of cervical infiltration and spread to lymph nodes and other organs in the pelvis 
and beyond (Table 2, Chpt 1.6).274,275 A multicenter study of more than 1200 patients 
supports that the FIGO stage 2009 classification has improved prediction of prognosis, 
and demonstrates that FIGO stage has independent prognostic impact also amongst FIGO 
stage I cases in multivariate survival analyses, when adjusting for histologic subtype and 
grade.351 The same study reports on 5-year survival of the various FIGO stages, ranging 
from 96% for stage IA to 16% for stage IVB, also demonstrated in a large register based 
study of more than 80 000 patients (Figure 11).352  
 
Figure 11. 5-year survival (%) from the different FIGO stages (2009); the numbers 
according to two studies.351,352 
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Molecular markers   
The molecular markers ER, PR, TP53, p16 and Ki67 are the prognostic biomarkers 
assessed by IHC most studied in endometrial carcinoma. Genomic analyses including 
DNA ploidy and copy number alterations and mutations have been increasingly studied 
the last decades, with a focus on PTEN, PIK3CA, KRAS and Her2, as elucidated below.  
Steroid hormone receptors 
Both estrogen and progesterone influence endometrial cell proliferation. The receptors of 
these ligands, estrogen receptor Į (ERĮ), ERȕ and progesterone receptor (PR) as well as 
GPER are studied in relation to their prognostic impact in endometrial cancer. An 
association between low ERĮ expression and survival was first demonstrated more than 
30 years ago.353,354 These findings are validated in several studies, also in multivariate 
survival analyses,123 although not yet included in the routine assessment directing therapy 
in endometrial cancers.30 Low ERȕ2 IHC expression is shown to associate with high 
FIGO stage and high Ki67, but not to survival.355 Low GPER expression is demonstrated 
to be associated with poor survival,228,356 also within the subgroup of ERĮ positive 
cases.228 Patients with low or absent tumor PR expression are associated with poor 
outcome compared to cases with PR expression.123,357 
Cell cycle and proliferation markers 
High expression of the cell proliferation marker Ki67 is demonstrated to be associated 
with clinico-pathologic variables of aggressive tumor phenotype,156,165,358 also with 
independent impact on survival when adjusted for clinico-pathologic variables and other 
molecular markers.165,359,360 High mitotic count, assessed by the cell proliferation marker 
PHH3 has been demonstrated to be independently associated with reduced survival.157 
High S-phase fraction (large proportion of cells in S-phase) is also associated with poor 
outcome.361-363 Low expression of p21, an inhibitor of cyclin-dependent kinases 
implicated in the cell cycle regulation, is associated with reduced survival in univariate 
but not multivariate survival analyses.165,364  
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DNA ploidy  
Aneuploidy, defined by an abnormal number of chromosomes in the cells, may reflect the 
general chromosomal aberrations experienced in cancer cells. DNA aneuploid tumors are 
demonstrated to be associated with a clinico-pathologic phenotype of aggressive cancer 
and reduced survival,148,365,366 also in subgroups of FIGO stage I tumors.367,368 DNA 
ploidy is also independently associated with prognosis in multivariate survival analyses 
(Table 4).369-371 DNA index > 1.2 is in a recent study associated with further reduced 
survival and distant metastases, compared to better survival and local recurrences in 
tumors with DNA index 1.06-1.2.365  
Table 4. DNA ploidy as prognostic marker: Overview of recent studies exploring the 
prognostic importance of DNA ploidy in endometrial carcinoma (studies from year 2000). 
          
Authorsa Yearb Prognostic impactc MVd FIGO included in MVe 
Sorbe B.371 2012 UV, MVh,i * * 
Pradhan et al.365 2012 UVf,h,j 
Song et al370 2011 UV, MVk * * 
Mangili et al369. 2008 UV, MVh * 
Susini et al.366 2007 UV, MVi,k * * 
Osmanagaoglu et al.372 2005 UVh * * 
Terada et al.373 2004 UVh,k 
Santala et al.374 2003 UV, MV * * 
Lundgren et al.375 2003 UVi 
Mangili et al.376 2002 UV, MV * 
Lundgren et al.377 2002 UV, MVk * * 
Jhala et al.378 2001 UV * * 
Nagai et al.379 2000 UVh * 
Footnotes:a Reference. b Year of publication. c Prognostic impact shown in Univariate (UV) or 
multivariate (MV) survival analyses. d MV survival analysis performed. e FIGO 1988 or 2009 included in 
MV survival analyses. f Endometrioid FIGO I/II, only. g Endometrioid FIGO I, only. h Overall survival.  
i Disease specific survival. j Progression free survival. k Recurrence free survival.  
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Hogberg et al. included DNA ploidy, myometrial invasion and a histopathologic score in 
a panel defining low or high risk endometrial carcinoma (serous and clear cell histology 
excluded).380 The high risk group, including DNA aneuploid cases, demonstrated 
significantly reduced survival and 50% of the progressions in this group were distant 
metastases, pointing to the importance of developing effective systemic therapies to this 
group. 
Tumor suppressor genes and markers of oncogenic pathways  
Mutations of TP53 and high IHC expression of TP53, a surrogate marker for TP53 
mutations, are overlapping in 76 % of endometrial carcinomas,381 and are associated with 
high FIGO stage and other markers for aggressive clinico-pathologic phenotype and 
reduced survival in this cancer type.165,167,382-384  
Inactivation of the tumor suppressor p16 as estimated by loss of protein expression is 
associated with poor prognosis in endometrial cancer. Deletions, point mutations and 
promoter hypermethylation are potential mechanisms of inactivation, and present in 
endometrial carcinomas.117,166,167  
Mutations in the tumor suppressor PTEN are the most frequent genetic alterations 
detected in endometrial carcinomas. Inactivating PTEN mutations are in the majority of 
studies of endometrial cancer associated with type I cancers, better survival and non-
aggressive clinico-pathologic features such as endometrioid histology in 
particular.64,103,104,385,386 Loss of PTEN function is described as an early event in the 
carcinogenesis from normal endometrium to endometrial cancer, being present also in 
atypical endometrial hyperplasia.387,388  
The oncoprotein Stathmin was initially suggested as a marker for PTEN loss in a breast 
cancer study389 and is suggested as a surrogate marker for PI3Kinase activation. Stathmin 
is recently identified as a strong prognostic marker in endometrial cancer.298,390 High 
Stathmin IHC expression (Figure 12) is associated with clinico-pathologic features of 
aggressive disease and reduced survival, also in multivariate survival analyses, adjusted 
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for traditional clinico-pathologic variables such as age, FIGO stage, histologic subtype 
and grade. High Stathmin expression in tumor tissue from pre-operative curettage also 
predicted lymph node metastases.298    
Figure 12. Reduced disease specific survival (A) in cases with Stathmin-high (C) 
compared to Stathmin-low (B) immunostaining. Reprint with permission, from Trovik et 
al.298  
 
Alterations of various PI3K pathway members such as PIK3CA mutations and 
amplifications have been identified in endometrial carcinomas.64,74,79,101,116 Furthermore, 
Salvesen and colleagues demonstrated that amplification of the 3q26 region, harboring 
PIK3CA, was associated with reduced survival in this cancer type.79   
Her2 protein overexpression is associated with reduced survival, also in various models of 
multivariate survival analyses, 107,391-393although other studies have not positively 
validated this finding.63 Her2 overexpression and amplification is more frequently 
occurring in non-endometrioid cancer,108,394  and more prevalent in serous carcinomas as 
compared to the other histologic subtypes within non-endometrioid carcinomas.395 Her2 
amplification is also shown to be associated with reduced survival in univariate survival 
analyses.393 Morrison et al demonstrated in a study of 483 endometrial carcinomas that 
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concurrent Her2 overexpression and amplification was independently associated with 
reduced survival when adjusted for clinico-pathologic factors such as age, histologic 
grade and FIGO stage.396  
EGFR overexpression is in some studies associated with reduced survival,108,397 although 
other studies have not demonstrated this association.398  
KRAS point mutations are found both in endometrial hyperplasia and endometrial 
carcinoma, indicating that KRAS might be important early in the carcinogenic 
development from hyperplasia to endometrial cancer.399 A recent study of 414 primary 
endometrial carcinomas and 61 metastatic lesions found KRAS amplification and high 
KRAS mRNA, but not KRAS mutations, associated with reduced survival.71 Also , in this 
study KRAS mRNA expression and the frequency of KRAS amplifications increased 
from primary to metastatic lesions.    
 
Biomarkers predicting therapy response 
Hormone receptor (ERĮ and PR) expression is suggested as markers predicting therapy 
response to hormonal therapy, such as Tamoxifen and progestagens. Recently two large 
literature reviews have evaluated hormonal therapy in the metastatic setting in 
endometrial cancer.335,336 Both studies conclude that trial design overall has been too 
unstructured and very few studies have stratified according to ERĮ and PR status when 
evaluating therapy response. However, a few studies have assessed the response 
according to hormonal receptor status and support ERĮ and PR as predictive markers for 
hormonal therapy.337,338 However, randomized controlled trials, stratified according to 
ERĮ and PR status are recommended to conclude in this matter.336   
Only approximately 10% of the presently ongoing clinical trials on targeted therapy in 
endometrial cancer are biomarker restricted (Tab 8, Chpt 1.8). As the focus on the 
importance of more molecularly based clinical trials and development of predictive 
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biomarkers in parallel is increasing, hopefully data from these and similar clinical trials 
will be explored in the search for valid markers predicting therapy response and further 
tested in new biomarker restricted clinical trials. 
In four of the 14 published phase I/II trials on targeted therapies in endometrial cancer, 
(Table 9, Chpt 1.8, hormonal therapy studies not included), potentially predictive markers 
have been assessed in the search for markers to select patients with response. In the study 
of the EGFR inhibitor erlotinib in 32 recurrent or metastatic endometrial cancer patients, 
none of the EGFR markers (IHC, amplification by FISH, mutations status) were 
associated with erlotinib response.400 In a study of mixed cancer types (in total 136 
patients; 15 endometrioid endometrial carcinomas), PIK3CA mutations and/or PTEN 
loss/mutation were suggested as predictive markers to combined 
bevacizumab/temsirolimus/liposomal doxorubicin, and this needs further evaluation in 
larger patient series.401  
In a study on 56 advanced endometrial cancer patients, the response to the VEGF-A 
antibody bevacizumab was suggested to be associated with low pretreatment plasma 
VEGF-A.402 However, the question whether VEGF-A is a potentially predictive marker 
for bevacizumab remains open. Her2 alterations (IHC expression and amplification by 
FISH) were evaluated as a potential predictive marker to the anti-Her2 antibody 
trastuzumab in 34 endometrial carcinoma patients. No major tumor response was seen, 
and neither Her2 IHC expression nor Her2 amplification was associated with survival.402 
Two recent studies including endometrial cancer and various other cancer types, have 
suggested the H1047R PIK3CA mutation as predictive marker for response to 
PI3K/mTOR inhibitors.73,403  
 
Gene expression signatures as biomarkers  
Global gene expression data may have a stronger potential to reflect the complexity of 
cancer biology as compared to the detection of single gene alterations, and also for 
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identifying markers for more complex biological processes taking place in the cancer 
cells. When taking the global expression pattern into account, we somehow compensate 
for the lack of knowledge regarding “the complete picture” of specific signaling pathways 
and the phenotypic consequences including potential compensatory mechanisms derived 
from their de-regulation. 
Gene expression arrays have the last ~15 years been increasingly applied in translational 
cancer research. Some of the first array studies within this research field demonstrated 
that gene expression data could identify both known and new molecular cancer subclasses 
with similarities in terms of biological behavior.404,405 In addition to identifying molecular 
phenotypes in various cancer types, such as breast, bladder and colorectal cancer,406-410 
the transcriptional alterations underlying the tumors examined have demonstrated to be 
powerful with respect to creating classifiers predicting cancer recurrences in breast and 
colorectal cancer,411-413 and to identify alterations in functional pathways and thereby 
suggesting relevant targets for therapy.414  
Analyses of the global transcriptional pattern in cancer have identified molecular 
subclasses associated with prognosis. The number of genes differentially expressed 
between classes has in many studies been reduced to a limited number of genes with 
maintained prognostic information presented as prognostic gene expression signatures. 
Such signatures (i.e. gene sets) might be regarded as metagenes with respect to expression 
value, and a signature score is calculated to evaluate the metagene expression value.415 
Other signatures than gene expression signatures have been published in cancer (e.g. sets 
of miRNAs, proteins or methylation sites unified by various means into the 
“signature”).416-418  Similarly, such signatures have been developed to predict response to 
specific treatment regimens.419-421  
Different methods for estimating gene expression signature scores have been 
presented.415,422 One method applied in several studies is presented by Huang et al:415 the 
gene expression values are normalized by subtracting a common mean from each 
74

expression value before these are scaled to the same standard deviation. The signature 
score is calculated by subtracting the sum of normalized expression values of genes 
expressed lower in one of the classes examined from the sum of expression values 
expressed higher in the same class, as illustrated in Figure 13. 
Databases of gene expression patterns according to various pathway and therapy specific 
perturbations are published.423,424 Gene-expression data from cancer samples can be 
mapped to such databases and analyzed according to how well the cancer sample 
expression data overlap with specific perturbations. Such tools may reveal connections 
between biological perturbations and tumor phenotypes that have yet been unknown.  
Other platforms, facilitating the gene expression exploration (both human and cell line 
data), are also publically available and may be a valuable tool in the search for 
transcriptional alterations pointing to targets and response to specific drugs.425-427 
A few gene expression signatures have been published for endometrial cancer. The first 
studies applying gene expression microarrays in endometrial cancer examined 
transcriptional alterations between endometrioid and non-endometrioid tumors.428,429 It 
was demonstrated that genes involved in endometrial homeostasis were higher expressed 
in endometrioid tumors, and genes involved in the regulation of mitotic spindle 
checkpoint were expressed higher in non-endometrioid cancer. Based on this, they further 
found that amplification of STK15 (=AURKA) was present only in non-endometrioid 
carcinomas.428 Risinger et al compared normal endometrium with cancer of endometrioid 
and non-endometrioid histology and pointed to IGF-1and a potential relation to 
PTEN/AKT, and summarized that some genes are altered in a histology subtype-specific 
manner, while other genes are similarly altered in endometrioid and non-endometrioid 
tumors.429 Both a knowledge-based study, comprising 492 endometrial carcinoma related 
genes in an array,430 and two studies of type I endometrial carcinomas, applying gene 
expression microarray technology covering 15-25 000 genes, have revealed 
transcriptional alterations pointing to biological processes previously unknown in this 
cancer subtype,431 and also a signature predicting survival is suggested.432 
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Figure 13. Illustration of one method to generate a gene expression signature score. A: 
Heat map showing genes differentially expressed between 2 clusters. B: A sum 
expression score is generated, subtracting the sum of down-regulated genes from the sum 
of up-regulated genes in one class/cluster.  
 
 
Salvesen et al reported a 29-gene signature that separated two clusters with different 
clinico-pathologic and molecular phenotypes as well as significant prognostic 
differences.79 A high signature score was associated with PI3K pathways alterations, 
suggesting patients with high signature score to be candidates for PI3K inhibitors. A study 
comparing transcriptional differences between endometrioid, serous and mixed mullerian 
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uterine carcinomas revealed distinct transcriptional patterns for each of the different 
histological subtypes.433 
A BMI-1 driven signature reported by Glinsky et al.434  was demonstrated to impact 
survival in endometrial carcinomas, more than BMI-1 mRNA expression.435 In a study by 
Mannelqvist and colleagues, an 18-gene signature derived from genes differentially 
expressed between endometrial carcinomas with and without vascular invasion, 
demonstrated prognostic impact.133 Furthermore, expression levels for selected 
angiogenesis related genes were demonstrated to be expressed higher in tumors with 
vascular invasion and gene sets representing epithelial-mesenchymal transition, wound 
response and VEGF activity were also enriched in tumors with vascular invasion.  
Experimental models have been used to create gene expression signatures mimicking 
activation of oncogenic pathways.415,436 It is demonstrated that such signatures might 
associate with prognosis and predict therapy response in cancer.436,437 The endometrial 
carcinoma 29-gene signature79 and the 18-gene vascular invasion signature133  are 
examples of signatures that indicate associations with druggable targets (PI3K, VEGF) 
but their potential as predictive markers for relevant inhibitors needs further testing in 
clinical trials. 
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1.8 Personalized medicine; targeted therapies and predictive markers 
“Targeted cancer therapies are drugs or other substances that block the growth and spread 
of cancer by interfering with specific molecules involved in tumor growth and 
progression.” (www.cancer.gov; National Cancer Institute, USA, October 2012) 
By directing therapy towards molecules specifically altered in cancer cells and to little 
extent altered in normal cells, the aim for the therapeutic strategy has been that the 
therapy will effectively kill the harmful cancer cell growth, while having less harmful 
effects in the normal cells. We have moved into the time for more personalized or 
stratified medicine, aiming to give the right drug to the right patient, at the right time. 
This therapeutic strategy has been increasingly focused the last decades. While this 
approach presently is being explored in large scale, the translation of research findings 
into clinical use has been somewhat more cumbersome, and the conventional therapies 
such as chemotherapy and radiotherapy still play the major role after surgery in the 
handling of endometrial cancer patients, with none of the new targeted therapeutics yet 
approved for standard clinical care, contrasting the improvements implemented for the 
cancer types like breast-, renal-, colorectal- and lung cancers (www.fda.gov). 
Estrogen receptor Į (ERĮ) was the first identified molecular target relevant for targeted 
therapy in cancer. An ERĮ antagonist (Tamoxifen) was developed and given to ERĮ 
positive breast cancer patients, and was the first and a very promising example of targeted 
cancer therapy. Other drugs that interfere with the binding of estrogen to ERĮ, drugs that 
interfere with synthesis of estrogen (aromatase inhibitors), and drugs promoting 
destruction of ERĮ (fulvestrant) have later been FDA approved for ERĮ positive breast 
cancer (www.fda.gov). The cloning and functional description of Her2 (ERBB2) was 
another early discovery, relevant for targeted cancer therapy in breast cancer. A 
monoclonal antibody is developed against Her2 (trastuzumab), also in clinical use today. 
Both ERĮ and Her2 are examples of markers associated with prognosis and prediction of 
response in breast cancer, and integrated as markers for treatment stratification in 
standard clinical breast cancer therapy today.   
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The majority of clinical studies evaluating the effect of new targeted therapies are per 
today performed according to a standard set-up starting with Phase I studies and 
continuing  to Phase II and III studies (Table 5).438 
Table 5: Overview of standard focus of clinical trials in oncology (after deBono 2010).438 
  
PHASE SIZE  FOCUS 
Phase I 20-60 Define safety, tolerability, MTD 
Describe dose-limiting toxicity 
Evaluate pharmacokinetic and pharmacodynamic relationships 
Phase II 30-200 Evaluate anti-tumor activity 
One cancer type; no stratification according to molecular  
tumor alterations 
Often non-randomized in oncology studies 
Phase III 400-2000 Designed to show a statistical benefit in clinical outcome, 
preferably overall survival 
    Usually unselected patient population; one tumor type 
 
In addition, post-marketing surveillance after clinical implementation of new therapy is 
performed as phase IV studies. These studies are carried out for specific disease 
subgroups, after the drug is approved for human use. Long-term effects of the drug in 
study might be assessed, and the drug effects amongst specific patient subgroups (e.g. 
pregnant women) may be explored, along with drug-interactions.     
 
What is a relevant target? 
Relevant targets for cancer therapy are ideally molecules that have an important role in 
cancer initiation, for cancer progression or for the metastatic tumor cells to “thrive” in the 
environment where they settle. Genetic addictions and other vulnerabilities and 
dependencies in tumor cells are exploited in the search for relevant molecular targets for 
therapy.439  
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We know there are multiple genetic and epigenetic aberrations in cancer. However, the 
concept “oncogene addiction” has been introduced describing a particular dependency in 
the cancer to one or a few genes to maintain a “cancer phenotype”440,441 In the search for 
relevant druggable targets, the “oncogene addiction” theory has been driving the strategy 
for a long period,442 and this approach has successfully contributed to the development of 
several important FDA approved drugs (e.g Trastuzumab/Her2, Gefitinib/EGFR).  
More recent studies in targeted cancer therapy have provided the concepts of “‘non-
oncogene addiction”,443,444 and “synthetic sickness/lethality”.445-447 “Non-oncogene 
addiction” genes are suggested as important in the search for relevant targets in cancer 
therapy as several of these genes and pathways are essential in the development and 
maintenance of the cancer phenotype, although not regarded as “drivers” in these 
processes.444 Inhibition of their corresponding proteins may thus impair cancer cell 
survival or other major important processes for the cancer to “thrive”. Luo and colleagues 
suggested categorization of “non-oncogene addiction” genes into: 1) tumor intrinsic and 
2) tumor extrinsic, where the genes support the oncogenic state by functioning within the 
tumor cell or through stromal and vascular cells surrounding the tumor, respectively.444 It 
is suggested advantageous to target the supportive cells as these are genetically more 
stable than the tumor cells, and also less likely develop drug resistance.444 The viability of 
normal cells is also to a large extent not dependent on such “tumor extrinsic” genes. 
The concept of “synthetic sickness/lethality” might be seen as an entity within the concept 
of “non-oncogene addiction”. “Synthetic sickness/lethality” takes advantage of co-
occurring gene alterations that together will impair cell viability, even if each defect alone 
would not affect the cell “fitness”.445 One textbook example of this is the demonstration 
of PARP inhibitors inducing synthetic lethality and thereby selective cytotoxicity to 
breast cancer cells with concomitant BRCA1 or BRCA2 mutations, also demonstrated in 
clinical studies.448,449 Both “non-oncogene addiction” and “synthetic lethality” are being 
explored in the search for relevant drug targets (Table 6).439  
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Table 6. Studies where “non-oncogene addiction” and “synthetic lethality” are exploited 
in targeted therapies.a  
      
Agent Target Reference 
17AAGb HSP90 450 
1MT, MTH_Trpb IDO 451 
5-fluorouracilc DNA 452 
AP12009 TGFɴ2 451 
AZD2281/AG014699b PARP1 453,454 
Bevacizumabc VEGF 455 
Bortezomib Proteasome 456 
Celecoxib COX2 451 
Cisplatin and analogsc DNA 457 
Mapatumumab/lexatumumab TRAIL receptor 458 
Methotrexate DHFR 459 
Paclitaxel/Vinblastinec Mitotic spindle 460 
PF-00477736b Chek1 461 
Rapamycin/temsirolimusc mTOR 462 
Sorafenib/Sunitinibc Multiple kinases 455 
Topotecan/Irinotecanc TOP1 463 
 
Footnotes:  a Adapted from Luo et al 2009,444 b Tested in endometrial carcinomas, c Tested in any solid 
tumors, www.clinicaltrials.gov (March 2013) 
HSP 90; Heat shock protein 90. IDO; indoleamin 2,3-dioxygenase. DNA; deoxyribonucleic acid. TGFȕ2; 
Transforming growth factor ȕ2. PARP1; Poly(ADP-ribose) polymerase 1. VEGF; Vascular endothelial 
growth factor. COX2; Cyclooxygenase-2. TRAIL; TNF-related apoptosis inducing ligand (=tumor 
necrosis factor (ligand) superfamily, member 10, TNFSF10). DHFR; Dihydrofolate reductase. Chk1; 
Checkpoint kinase 1. mTOR; Mechanistic target of rapamycin. TOP1; Topoisomerase 1. 
 
It has been shown to be a challenging task to identify a target that has such an important 
role in human cancer that directing therapy towards it has the potential to “cure the 
cancer”. When studying patients and tumor tissues from patients, the best studies we do 
today are association studies; we study the association between a marker (a potential 
target) and for example histopathologic variables and clinical parameters, including 
outcome (e.g. risk of recurrence or progression and survival). The majority of these 
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patients are not treated with any drug considered to specifically aim for the target 
investigated. How are we able to identify molecules that are crucial for the cancer to 
“thrive”? In cell lines and mouse models, we do this by engineering functional models 
considered to mimic molecular changes seen in patient samples. But how well do the 
results from these functional models reflect the situation in the cancer patients?  
Genome-scale RNA interference (RNAi) screenings of cell lines are supported as a robust 
method to identify candidate targets. Use of genome-wide RNAi screens has been able to 
point to genes that are important for the specific process studied (e.g. drug resistance) 
without being for example mutated, as will be valid for many of the “non-oncogene 
drivers”.444 This is an advantage of the method above the next generation sequencing that 
takes place in larger and larger scale in cancer research: non-mutated, but nevertheless 
important genes will not be caught in the latter investigation. A limitation of the RNAi 
screen is that per today it is only performed in cell lines. 
Cancer cell lines and mouse models have been found to be useful tools when studying 
specific cell biological mechanisms. By interfering with the genotype and molecular 
phenotype (e.g. overexpressing or knocking down a gene), we are able to read how these 
forced changes may lead to other expected or unexpected molecular alterations. Cell line 
studies have often been the starting point for the targeted drugs that have been developed, 
and are together with mouse models regarded of importance when identifying and testing 
how to influence relevant targets for therapy.464 Still, cell lines are somehow artificial 
cancer models, as these models mainly consist of only one or a few cell types. The tumor 
microenvironment surrounding the cancer cells is demonstrated to be of importance for 
the cancer growth, but is rarely accounted for in the models. Thus, important interaction 
between cancer cells and surrounding microenvironment cells that takes place in a tumor 
may go undetected. It is today recognized that cell line studies have limitations as cancer 
models, for example when studying therapy response.439  
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In the majority of preclinical cell line models presented until now, too few cell lines have 
been studied to be able to evaluate drug response in relation to tumor heterogeneity, 
regarding both the various cancer subtypes and the genetically heterogeneity seen.465 
Recently, two comprehensive studies on cell line panels were published; 639 and 947 cell 
lines were molecularly annotated by sequencing candidate genes, assessing copy number 
variations (CNV) and gene expression data. The cell line data were linked to drug 
sensitivity data of a range of compounds, and the studies suggested new drug sensitivity 
biomarkers.425,426 The data generated in these studies is made publically available 
(http://www.broadinstitute.org/ccle; http://www.cancerrxgene.org/). Comments to these 
works have highlighted the important contributions of the studies as examples of how 
such large, diverse cell line panels together is a model that match the molecular tumor 
heterogeneity we experience.466-468 Despite limitations of cell lines in culture, in terms of 
being models for human cancer, studies of such large cell line panels are also able to point 
to cancer cell vulnerabilities and thereby new relevant targets for therapy combined with 
markers predicting therapy response.466,467  
Genetically engineered mouse models and xenograft models of mice transplanted with 
human tumor tissue are promising models when validating molecular findings from 
patient tumor tissue and functional cell line studies.464 These models may allow 
investigation of factors involved in malignant transformation, invasion and metastasis, as 
well as testing for response to therapy. In human tumor xenografts, the human tumor cells 
may be transplanted into immunocompromised mice (to avoid rejection) under the skin or 
in the orthotopic model, into the organ type the tumor originated from.  
Important to remember, when interpreting the results from mice studies in light of the 
human cancer biology; mice are not men. Limitations such as lack of tumor diversity are 
seen in some mouse models of cancer, and introducing genomic instability might aid to 
resolve this problem.465 Also, the lack of an adequate responsive immune system in the 
immunocompromised mice, might be a weakness when examining the muse models, and 
aiming to mirror the cancer biological processes in human.  
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A key challenge is to identify important drivers in the carcinogenic process and how to 
target these processes. If such a potential target is suggested based on pre-clinical models, 
a next step may be to investigate further the presence of the candidate marker in patient 
tumor tissues in relation to patient outcome. If the identified marker is enriched in 
samples from patients with aggressive disease and poor survival, it is more likely that you 
will be able to recruit sufficient number of cases to test for effects from targeting the 
alteration in a metastatic setting. Still, a crucial question is whether the alteration only 
“co-associates” to the aggressive phenotype OR drives the aggressiveness of the tumor. In 
the first case, targeting this marker will probably not be helpful. The inevitable ultimate 
step to determine the relevance of the target for new therapeutics is to evaluate if 
drugging the target will lead to therapeutic effects in patients in a controlled clinical 
trial.439 Studies that has led to FDA approved targeted therapies have pointed to molecular 
alterations of the cancer cells not shared by normal cells, being potential targets for 
therapy with specific drugs. Some examples of such studies are listed in Table 7.   
 
 
 
 
 
 
 
 
 
 
84

Table 7. Examples of FDA approved targeted therapies, and reference studies 
(www.cancer.gov/cancertopics/factsheet/Therapy/targeted). 
        
Primary  
Drug Trade Name target(s) Primary indication 
Signal transduction inhibitors 
Trastuzumab Herceptin  Her2 Her2 positive metastatic breast cancer469 
Imatinib Gleevec ABL, cKIT BCR-ABL translocation-driven CML470 
Gefitinib Iressa EGFR EGFR-driven NSCLC471 
Erlotinib Tarceva EGFR NSCLC; pancreatic carcinoma472 
Cetuximab Erbitux EGFR Head and neck squamous cell carcinoma 473 
KRAS wt colorectal cancer474 
Panitumumab Vectibix EGFR KRAS-wt colorectal cancer475 
Temsirolimus Torisel mTOR Renal cell carcinoma476 
Lapatinib Tykerb ERBB2/EGFR Her2-positive breast cancer477 
Everolimus Afinitor mTOR 
Giant cell astrocytoma;478 renal cell 
carcinoma479 
PNET480 
Crizotinib Xalkori ALK ALK-rearranged NSCLC481 
Vemurafininb Zelboraf BRAF V600E BRAF-mutated melanoma482 
Angiogenesis interference 
Bevacizumab Avastin VEGF Metastatic colorectal cancer483
Sorafenib Nexavar VEGFR Hepatocellular carcinoma;484 
renal cell carcinoma485 
Sunitinib Sutent VEGFR renal cell carcinoma;486 PNET487 
Ziv-aflibercept Zaltrap VEGF Metastatic colorectal cancer488 
Modulate protein function 
Vorinostat Zolinza HDACs Cutaneous T-cell lymphoma489 
Bexarotene Tagretin RXR Cutaneous T-cell lymphoma 
Tretinoin Vesanoid RAR 
Induce apoptosis 
Bortesomib Velcade proteasome muliple myeloma;490 
Modulate immune response 
Ipilimumab Yervoy CTLA-4 unresectable or metastatic 
melanoma491 
Rituximab Rituxan CD20 B-cell non-Hodgkin lymphoma;492 
      chronic lymphocytic leukemia493 
Footnotes:*FDA approved in combinatorial therapy (www.fda.gov).  
FDA=Food and Drug Administration (USA), CML= chronic myeloid leukemia. NSCLC= non-small-cell 
lung cancer. VEGF= vascular endothelial growth factor. VEGFR=vascular endothelial growth factor 
receptor.GIST=gastrointestinal stromal tumor. PNET=pancreatic neuroendocrine tumor. wt= wild-type. 
CTLA-4=cytotoxic T-lymphocyte-associated antigen-4. RXR= retinoid X receptor. RAR=retinoic acid 
receptor.  
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Targeted therapies in endometrial cancer 
For endometrial cancer, the number of ongoing clinical trials are far less (~350) than for 
ovarian- and breast cancer; >1300 and >4500 studies, respectively, based on all reported 
clinical trials at the www.clinicaltrials.gov (October 2012). For endometrial cancer, 
several clinical trials on targeted therapies are ongoing. These are mainly phase I and II 
trials, and are exploring effects of PI3K/mTOR pathway inhibitors, PARP and 
angiogenesis inhibitors (Table 8).   
Table 8. Overview of ongoing clinical trials on targeted therapy in endometrial cancer 
(www.clinicaltrials.gov, October 2012). 
            
Additional Biomarker 
Target Biological agent ID therapy N Restriction 
AKT MK2206 NCT01307631 90 PIK3CA mut. 
AKT MK-2206 NCT01312753 90 PIK3CA mut. 
AKT/MEK GSK2141795/GSK1120212 NCT01138085 125a 
AKT/MEK GSK110183/GSK1120212 NCT01476137 335a 
ALK1 ligands Dalantercept NCT01642082 52 
Angiopoetin ½ AMG386/trebananib NCT01210222 55 
ER Endoxifen NCT01273168 72a ER/PR pos 
ER/PR BN83495/MA NCT00910091 73 
ErbB3 MM-121 NCT01209195 P 24a 
FGFR2 TKI258 NCT01379534 80 
Her2 Lapatinib NCT01454479 I 24 Her2 pos 
Her2 Trastuzumab NCT01367002 C/P 100 Her2 pos 
mTOR Ridaforolimus NCT00770185 30 
mTOR/CYP19A1 Everolimus/Letrazole NCT01068249 42 
mTOR Ridaforolimus NCT01256268 C/P 28a 
mTOR temsirolimus NCT01155258 VD 19a 
mTOR temsirolimus NCT00982631 PLD 30a 
mTOR/angiopoetin 
1/2 temsirolimus/AMG386 NCT01548482 42a 
mTOR/ER/PR Temsirolimus/MA/TC NCT00729586 84 
mTOR/Notch  temsirolimus/RO4929097 NCT01198184 30a 
PARP olaparib NCT01237067 C 66a 
PARP ½ MK-4827 NCT00749502 113a 
PARP ½ veliparib NCT01366144 C/P 276a 
PI3K XL147 NCT01013324 88 
PI3K BKM120 NCT01397877 56 
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Contd. Table 8      
 
Additional Biomarker 
Target Biological agent ID therapy N Restriction 
PI3K XL147 NCT00756847 C/P 74a 
PI3K GSK2636771 NCT01458067 150a PTEN loss 
PI3K BKM120 NCT01068483 83a 
PI3K/mTOR PF-04691502/PF-05212384 NCT01420081 269 
PI3K/mTOR DS-7423 NCT01364844 66a 
PI3K/mTOR GDC-0980 NCT01455493 50 
PI3K/mTOR PKI-587 NCT00940498 85a 
PR MPA NCT01594879 LNG 39 
PR/AMPK LNG/metformin NCT01686126 111   
RTKs E7080 NCT01111461 133 
RTKs Dasatinib NCT01440998 15 
VEGF Bevacizumab NCT00879359 C/P 31 
VEGF/mTOR Bevacizumab/Temsirolimus NCT00977574 C/P/I 330 
VEGFRs/PDGFRs/KIT Sunitinib malate NCT00478426 30 
VEGF Bevacizumab NCT00513786 C/P 38 
VEGFR/FGFR/PDGFR BIBF 1120/nintedanib NCT01225887 55 
VEGFR/FGFR Brivanib alaninate NCT00888173 43 
VEGFR cediranib maleate NCT01132820 54 
VEGF-A/VEGF-B/PlGF ziv-aflibercept NCT00462826 43 
VEGF/mTOR Bevacizumab/temsirolimus NCT00723255 43 
VEGF/mTOR cediranib/temsirolimus NCT01065662 50a 
VEGF/mTOR bevacizumab/temsirolimus NCT01010126 299a 
VEGFRs/PDGFRs/KIT sunitinib malate NCT00813423 HC 20a 
CYP19A1 Letrozole NCT00997373   50   
 
Footnotes: ID= Clinicaltrial.gov identifier. N= Number of patients to be included. a Other cancer types included in 
the study. C/P=Carboplatin/Paclitaxel. I= Ixabepilone. VD= Vinorelbine ditartrate. PLD= Pegesylated Doxorubicin. 
LNG= levonorgestrel (intra uterine system). HC= Hydroxychloroquine 
 
Published and preliminary study results (conference/abstract presentations) from targeted 
therapies in endometrial cancer mainly report on studies targeting mTOR and 
VEGF/VEGFR (Table 9). The response rates are overall modest, and the studies could 
potentially have benefited from biomarker stratification, as further discussed below. Only 
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a few of these studies have assessed molecular alterations in pre-treatment biopsies and 
evaluated therapy response according to such information.400-402,494 
Table 9. Published phase I/II trials on targeted therapy in endometrial cancer (per 
October 2012, except hormonal therapy covered in Chpt 1.6).  
                      
Prior Add CR PR SD median PFS 
Ph Drug Target Na therapy ther (%) (%) (%) (range)b Ref 
II Cetuximab EGFR 30  4 CT   0 5 10 495 
II Erlotinib EGFR 32 CT=0 0 12.5 46.9 3.7 (2-36) 400 
II Trastuzumab Her2 33 UL CT 0 0 40 1.8 (range NR) 494 
II Temsirolimus mTOR 54 
A) 
CT=0 0 A) 14 A) 69 5.1 (3.7-18.4) 496 
ч1 HT 
B) 1 CT  0 B) 4 B) 46 B) 4.3 (3.6-4.9) 
II Everolimus mTOR 28  2 CT  0 0 43 4.2 (1.8-9.3) 497 
II Deforolimus mTOR 27  2 CT  7 26 NR 498 
II Ridaforolimus mTOR 130  1 CT  0 35 3.6 499 
I Temsirolimus mTOR 11  2 CT  C/P 0 91 NR NR 500 
I Bevacizumab/ VEGF-A/ 15 CT LD 40c     53d NR 
401 
Temsirolimus mTOR  
II Bevacizumab VEGF-A 52  2 CT   2 12 4.2 (range NR) 402 
+/- RT 
II Aflibercept VEGF/PlGF 44  2 CT   0 7 32 2.9 (0.3-18) 501 
II Sunitinib VEGFR 20  1 CT  0 15 25 NR 502 
II Sorafenib VEGFR 55  1 CT    0 4 42 2.3 (range NR) 503 
           
Footnotes:  
Abbreviations: Ph=Clinical trial phase, Add ther = additional therapy, CR= complete response, PR= partial response, 
SD = stable disease, PFS = progression free survival, HT= hormonal therapy, CT = chemotherapy regimens, NR = 
not reported, LD = liposomal doxorubicin, C = carboplatin, P = paclitaxel, HT = hormonal therapy regimens, 
RT=radiation therapy, ref.=reference, NL=no limitations. a number of endometrial cancer patients evaluable, b PFS= 
Progression free survival (months), c CR or PR, d SD 6 months/PR/CR.  
 
 
 
88

Why has there been a limited effect of targeted therapies so far? 
“All models are wrong, but some are useful” (George Box 1979) 
The lack of biomarker stratified clinical trials might have been one of the “strategic 
mistakes” done in the approach to testing for effect from molecularly targeted 
therapeutics in cancer treatment. Arguments for not applying a molecular basis for 
treatment stratification have been uncertainties regarding the link between the presumed 
target and the actual drug tested, often found to have multiple target activities. Also, 
preclinical models have been difficult to translate into adequate clinical trial design in 
humans. Still, important arguments for improved trial design are that the development and 
testing of drugs is extremely expensive, and with the large number of drugs in the pipeline 
to be tested, unselected testing of all drugs will not be able to recruit sufficient number of 
patients. Drug companies might have hoped for better overall response rates when testing 
new drugs in clinical trials without biomarker stratification, but the experience so far and 
costs related to this approach may limit this in the future. The idea of targeted therapeutics 
is that the drug targets a specific molecular phenotype that is important to the tumor cell. 
If the patient receiving the drug does not have tumor(s) with this specific molecular 
phenotype, it is not likely that she will respond to the drug. 
How to consider targeted therapy in the metastatic setting, when available results from 
molecular analyses is present only for the primary tumor? If the primary tumor is positive 
for the marker of interest, one pragmatic approach is not to biopsy any metastases because 
a negative result will not prevent therapy from being given. A negative metastasis with 
respect to the marker in question is not reassuring for any metastasis being negative for 
the marker. As clones in primary tumor have demonstrated to be positive for the marker, 
these may also metastasize. However, if the primary tumor was negative for a marker that 
would indicate therapy if positive, biopsies from metastatic lesions are recommended if 
achievable, as a positive marker in a metastatic lesion would lead to therapy being given. 
Per today we are not taking into account the challenge of intratumor heterogeneity or 
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tumor cell evolution.504,505 These are issues that also have to be addressed properly in 
relation to targeted therapy the coming years.  
We know the biology is complex, and the biology of cancer cells maybe even more 
intricate, as genomic instability is one of the hallmarks of the cancer cells,10 and which 
genes and pathways that are overactive may switch as the tumor develops.504 When 
knowing this, isn’t it likely that mono-targeting a receptor tyrosine kinase is insufficient 
for a large proportion of the patients?  Combinatorial therapy in cancer has mainly been 
focused to combinations of chemo/radiation and a molecular targeted drug. Even in the 
case of Trastuzumab to Her2 positive breast cancer, regarded as an example of success in 
the history of targeted therapies, 25-30% of Her2 positive cases progress on Trastuzumab 
and chemotherapy.506 The concern of drug resistance, both de novo and acquired 
resistance has probably been one of the reasons for limited effect of targeted therapies on 
overall survival. This issue is now being addressed and in some studies the drug 
combinations are designed trying to overcome the problem of resistance. Berns and 
colleagues demonstrated by RNAi screen of untreated breast cancer cell lines versus cell 
lines treated with Trastuzumab that low expression of PTEN was associated with lack of 
therapy response.507 In line with this, a phase I/II study on everolimus (mTOR inhibitor) 
and Trastuzumab to patients with Her2 overexpressing metastatic breast cancer 
demonstrated promising results 506  
As targeted drugs are often given in combinations with conventional therapy, it might be 
of importance how the drugs are combined. A phase III trial on adjuvant chemotherapy 
and tamoxifen to breast cancer patients demonstrated that the two drugs given 
sequentially gave a favorable hazard ratio, although not statistically significant, as 
compared to when the drugs were given concurrently.508 Depending on the rationale for 
giving targeted drug(s) in combination with chemo or radiation therapy or combinations 
of several targeted drugs, the timing for drug delivery is probably of importance, and 
understudied per today.509    
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2. AIMS OF THE STUDY 
 
2.1 Background 
Endometrial cancer is diagnosed early and has in general good prognosis. The more 
important it is to diagnose and treat the poor-prognosis cases. Therapy of endometrial 
carcinoma patients per today is to a large extent empirically based. Improvements on 
therapeutic strategies with more personalized focus are needed; what kind of therapy 
(conventional versus targeted) should be given when (e.g. localized versus systemic 
disease), and to whom (all patients versus defined risk groups)? It is well known that 
development of new therapies to appropriate patient groups is a demanding and time-
consuming task exemplified by the identification of Her2 as target and development of 
Trastuzumab for patients with Her2 positive breast cancer. Preparing the ground for later 
clinical studies, by combining clinico-pathologic and molecular data from preclinical 
studies and cancer patients, is an important step to individualize therapy in cancer. 
The incidence of endometrial cancer is increasing5 and the prognostic categorization used 
in clinical practices today is suboptimal for separating patients according to survival.28-30 
Despite a focus on translational research in endometrial cancer for some decades, it has 
proven difficult to bring new biomarkers to the clinic to improve prognostication and 
prediction of therapy response in this cancer type.30,64 The type I/II categorization is used 
world-wide, based originally on a clinical-descriptive study 30 years ago,27 although 
molecular characteristics for the two groups have been related to microsatellite instability 
and PTEN, p16, TP53, ERĮ, PR and PI3K pathway alterations.64 Endometrial cancer is 
behind other cancer types as breast, lung and colorectal cancer in clinical application of 
molecular classification of tumors to select patients for targeted therapy.30,64 Better tumor 
biological understanding of subgroups, applicability of prognostic markers in a routine 
clinical setting, and identification of targets for therapy including markers predicting 
response to such, are important to improve personalized treatment strategies to benefit the 
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endometrial carcinoma patients.  
 
2.2 General aim 
The main goal of this project was to study biomarkers potentially associated with 
endometrial carcinoma progression, to assess their potential as prognostic markers and 
explore on targets for therapy associated with pathologic expression of these markers. By 
this, we aimed to provide a rationale for further testing of candidate markers as prognostic 
and predictive markers in clinical trials.  
A second aim has been to focus on biomarker implementation through an important step 
in the stair-case from research to clinical use; biomarker validation in independent patient 
series and in a routine clinical setting.  
 
2.3 Specific aims 
1. To investigate the prognostic impact of DNA ploidy in endometrial carcinoma in a 
routine diagnostic compared to a research setting. (Paper I). 
 
2. To explore whether low ERĮ expression, associated with poor prognosis in 
endometrial carcinomas, was reflected in transcriptional signatures pointing to 
tumor biological processes important for cancer progression, and with a potential 
as targets for new therapy (Paper II). 
 
3. To study how pStathmin(S38) immunohistochemical expression correlated with 
prognosis in endometrial cancer. Also, we wanted to explore on transcriptional 
changes associated with pStathmin(S38) expression to uncover tumor phenotypic 
alterations associated with pStathmin(S38) and to potentially suggest targets and 
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predictive markers for novel therapeutics in aggressive endometrial carcinoma 
(Paper III).  
 
4. To validate prospectively in independent patient series the ability for a previously 
defined endometrial cancer risk of recurrence signature to predict disease relapse 
in general and amongst presumed low risk groups in particular. We also wanted to 
assess the correlation between the signature score and potential measures for PI3K 
signaling, hormone receptor status and other potential targetable factors involved 
in the process of tumor progression (Paper IV).  
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3. MATERIAL AND METHODOLOGICAL CONSIDERATIONS 
“Whether you can observe a thing or not depends on the theory which you use. It is the 
theory which decides what can be observed.” (A. Einstein 1879-1955)  
3.1 Patient series and tissues  
Overall, two major patient series are studied in this project; 1) A retrospectively collected 
series of 286 cases, all verified endometrial carcinoma patients diagnosed in Hordaland 
County in the period 1981-1990. Hordaland County covers approximately 10% of the 
Norwegian population510 and has the same age-adjusted incidence rate for endometrial 
cancer as the whole Norwegian population.4 Initially 316 patients were diagnosed with 
endometrial cancer in Hordaland County this time period. Twelve of these were excluded 
due to altered diagnosis after histopathologic revision, and 5 more cases were diagnosed 
by cytology only and therefore also excluded. For the remaining 299 cases, paraffin 
blocks from primary tumor were accessible for 286 patients.117 This series is described as 
a population based series and has been extensively studied and described.104,117,120,155,390  
2) From 2001 onwards, patients from several Norwegian and European gynecologic 
oncology centers have consented and been prospectively enrolled in the MoMaTec study 
(http://www.clinicaltrials.gov/ct2/show/NCT00598845). Patients from Haukeland 
University Hospital have been studied in this project, and were enrolled from May 2001 
to January 2011. An overview of the patients studied and tissues/methods applied is given 
in Figure 14, Table 10 and Table 11. 
Clinical data 
For both major cohorts studied, clinical data covering parity, menopausal status, height 
and body weight, age at primary diagnosis, date of diagnosis, type of primary and 
adjuvant treatment, FIGO stage (according to 1988 criteria for the retrospective cohort 
and 2009 criteria for the prospective cohort, except for Paper I where FIGO 2008 was 
applied), and information about lymph node sampling were collected from patient files.511 
Imaging diagnostics was retrieved from routine radiological reports for both cohorts. 
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Complete follow-up information was recorded, including date and site of recurrent and/or 
progressive disease and therapy of such, and patient survival with status at last date of 
follow-up. Supplementary follow-up information was collected from out-patients medical 
doctors responsible for parts of the follow-up.511 Last date of follow-up for the 
retrospective cohort was June 30th 2004. For the prospective cohort, the follow-up month 
was November 2008/Paper I, November 2010/Paper II, June 2011/Paper III and IV.  
Figure 14. Overview of the Haukeland based patient series and methods applied in the 
project 
 
IHC: immunohistochemistry, qPCR: quantitative polymerase chain reaction, SNP: single nucleotide 
polymorphism, FISH: Fluorescence in situ hybridization. 
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The primary treatment for both patient cohorts has been hysterectomy and bilateral 
salpingo-oophorectomy. Radical hysterectomy (ad modum Wertheim-Meigs) has been 
performed in cases with cervical/paracervical infiltration identified pre-/peroperatively. In 
the retrospective cohort, lymph node sampling was not routinely performed, but enlarged 
nodes suspect of malignancy were biopsied. Lymph node sampling has increasingly from 
2001 been part of the standard surgical treatment recommended to endometrial carcinoma 
patients.237,317 Patients not suitable for surgical treatment were staged by clinical 
examination, curettage and x-ray/CT results. These patients were offered radiotherapy or 
hormonal therapy in the retrospective cohort and radiotherapy, chemotherapy and/or 
hormonal treatment in the prospective cohort. Adjuvant radiotherapy was part of the 
standard treatment in the period 1981-90; brachytherapy to cases with myometrial 
infiltration <50%, external pelvic radiation to cases with deep myometrial infiltration 
and/or high histologic grade.317 In the prospective cohort, external radiation therapy and 
chemotherapy has been given as adjuvant treatment to patients with high risk of 
recurrence (e.g. non-endometrioid histology, high histologic grade and deeply infiltrating 
tumors).237 Only a few cases received adjuvant chemo-radiation in the prospective cohort. 
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TABLE 10: Comparison of clinico-pathologic data in the retrospective and complete 
prospective series. 
        
Hordaland population 
Haukeland  
population 
1981-1990 2001-2010 
Retrospectively collected Prospectively enrolled 
N=286 N=620 
  n (%) n (%) Pa 
Mean age, years (range)  65   (33-92)  66 (28-94) 0.6 
Menopausal status 
  Pre-/perimenopausal   43 (15)   75 (12) 0.2 
  Postmenopausal 242 (85) 545 (88) 
FIGO 1988/2009 0.5 
  I-II 230 (81) 521 (83) 
  III-IV   55 (19) 108 (17) 
Histologic typeb,c < 0.001 
  Endometrioid 257 (90) 486 (78) 
  Non-endometrioid   29 (10) 134 (22) 
Histologic grade c < 0.001 
  1-2 218 (76) 399 (65) 
  3   68 (24) 216 (35) 
Myometrial infiltration 0.5 
  < 50% 146 (62) 377 (64) 
   50%   90 (38) 210 (36) 
Lymph node metastases Not assessed 
  Absent 426 (69) 
  Present   55  (9) 
  Not examined 139 (22) 
Recurrenced 
  No 224 (83) 465 (85) 0.6 
  Yes   46 (17)   85 (15)   
Footnotes: Missing cases: Menopausal status 1 case and FIGO stage 1 case retrospective series, 
histologic grade 5 cases in the prospective series. Myometrial infiltration data available for 236 cases in 
the retrospective series and 587 cases in the prospective series. a Chi square test applied except for 
comparison of age where Mann-Whitney U test applied. b Carcinosarcomas included in the non-
endometrioid group for the prospective series. c Revised pathology diagnosis. d Without metastatic disease 
at primary diagnosis.  
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External gene expression data set 
Gene expression data are generally required to be added to publically available 
repositories when published first time (e.g. GEO, http://www.ncbi.nlm.nih.gov/geo/, 
ArrayExpress, http://www.ebi.ac.uk/arrayexpress/). For this study, a data set comprising 
111 endometrial cancers with basic clinico-pathologic data available were used. These 
samples were run at Affymetrix U133 Plus2 arrays. The data set had been downloaded 
and normalized in a previous work in our group. Individual probes were then sequenced 
matched against AceView (NCBI35),512 to construct transcript level probe sets.79 A 
quality check on updated clinico-pathologic data, confirmed 111 endometrial carcinomas 
that were included in Paper II. 
The Cancer Genome Atlas (TCGA) data 
Collaborators in the project have analyzed gene expression levels from RNA sequencing 
in the 29-gene Endometrial Carcinoma Recurrence Score in 333 patient tumors.513 
 
Tissues 
Snap frozen fresh tissue 
In Paper II, III and IV fresh tissue that was snap frozen after surgery was used for 
mRNA expression analyses (DNA oligonucleotide microarray and qPCR): 76 (Paper II) 
and 122 primary tumors (Paper III and IV) were analyzed on DNA oligonucleotide 
microarrays. Also, mRNA was extracted from 19 metastatic lesions (Paper IV). In Paper 
II and IV, qPCR was applied for 155 and 158 cases, respectively. 
Fresh ethanol fixed tissue 
Fresh ethanol fixed tissue was used for DNA ploidy analyses in Paper I and Paper III. 
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FFPE samples  
Tissue samples fixed in formalin and embedded in paraffin were retrieved from the 
archives of Department of Pathology, The Gade Institute, Haukeland University Hospital. 
FFPE samples were applied for immunohistochemical studies (Paper II and III), and for 
data previously published.120,124,155,228,298   
 
3.2 Histopathologic data 
Histopathologic data such as histologic type, pattern of spread, histologic grade and 
myometrial infiltration was recorded.511 For the retrospective cohort and a subset of 76 
cases from the prospective series (described in Paper II, III and IV), histopathologic 
data were revised by two experienced pathologists (I.M.S. and L.A.A.).155 For the 
prospective series apart from the subset of 76 cases, data were retrieved from routine 
pathology reports. Histologic subtyping and determination of histologic grade was 
reported according to WHO criteria.265 Myometrial infiltration was evaluated by 
microscopy and was measured as vertical tumor thickness in the myometrium divided by 
the full thickness of the myometrium (measures in mm). The number of mitoses (mitotic 
count) was counted in 10 high-power fields (x400) by selecting areas with the highest 
histologic grade and highest mitotic activity (“hot spots”). Vascular invasion was defined 
as present if invasion in more than one vessel or vascular space was seen.155  
In the retrospective cohort, carcinosarcomas were not included as these were regarded and 
treated as a sarcoma subtype in this time period. This histologic subtype of endometrial 
cancer was in the late 90’s suggested to be of monoclonal epithelial origin and as a 
consequence, patients with carcinosarcomas have been treated as high-risk endometrial 
carcinomas in the prospective cohort,237,514 and were therefore included amongst the non-
endometrioid cases in this patient series. When excluding the carcinosarcomas (n=24) 
from analyses as performed in Table 10, there is still a significant difference in the 
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distribution of histologic subtypes for the two cohorts (more non-endometrioid cases in 
the prospective cohort, P=0.008) and thereby as expected, also more cases of high 
histologic grade in the same cohort.  
 
Table 11. Patient series, tissue types, methods applied and biomarkers assessed in the 
different papers.  
Paper Patient cohort/N Tissue Biomarker Method Evaluable/N 
I 1981-90/286 Fr. ethanol fixed DNA ploidy Flow cytometry 101 
2001-2007/427 Fr. ethanol fixed DNA ploidy Flow cytometry 262 
II 1981-90/286 FFPE ERĮ IHC 266 
E-cadherin IHC 284 
P-cadherin IHC 276 
ȕ-catenin IHC 286 
Catenin p120 IHC 276 
2001-2010/620 
Fr. frozen DNA microarray 76 
ESR1 qPCR 155 
E-cadherin qPCR 155 
P-cadherin qPCR 155 
N-cadherin qPCR 155 
ȕ-catenin qPCR 155 
Catenin p120 qPCR 155 
Į-catenin qPCR 155 
3q26 amplif. SNP array 70 
PIK3CA mut.status PIK3CA seq. 245 
  
External gene 
expression data/111   DNA microarray 
 
III 1981-1990/286             FFPE pStathmin(S38) IHC 256 
Ki67 IHC 196 
PTEN IHC 279 
Mitotic count Morphology 286 
S-phase Flow cytometry 64 
2001-2010/620 FFPE pStathmin(S38) IHC 518 
3q26 amplif. SNP array 70 
PIK3CA copy no. FISH 66 
PIK3CA seq. 245 
    Fr. frozen   DNA microarray 122 
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Contd. Table 11     
IV 2001-2010/620 Signature score DNA microarray 122 
Fr. frozen Signature score qPCR 158 
E-cadherin qPCR 155 
P-cadherin qPCR 155 
N-cadherin qPCR 155 
ȕ-catenin qPCR 155 
Catenin p120 qPCR 155 
Į-catenin qPCR 155 
IV 2001-2010/620 Fr. frozen 3q26 amplif. SNP array 70 
PIK3CA copy no. FISH 66 
      PIK3CA seq.   245 
TCGA data Signature score RNA seq. 333 
Abbreviations: Fr.=fresh, FFPE=Formalin fixed and paraffin embedded, mut.status=mutation 
status, Copy no.=copy number, seq.=sequencing, TCGA=The Cancer Genome Atlas  
 
3.3 Immunohistochemical methods 
Immunohistochemical staining is widely used to assess protein expression in routine 
pathology diagnostics and research. A morphologic description is pivotal for the diagnosis 
of cancer. Immunohistochemistry may be a relevant addition to the morphologic 
examination as IHC may reveal cellular localization and degree of expression of epitopes 
under study, and may point to functional changes in tumor tissue. IHC is demonstrated to 
be an important tool in biomarker studies.515  
 
Tissue sections and tissue microarray (TMA) 
FFPE sections of 5μm were used for immunohistochemistry (IHC), taken either from 
standard paraffin blocks or from TMA blocks. The technology of tissue microarray 
(TMA) was first described by Battifora in 1986,516 but use of the technique took off when 
Kononen et al developed a device for rapid, good-quality TMA production.517,518 By using 
TMA, the experimental performance will be more uniform, there is an economization of 
both tissue and material used as well as time spent to evaluate large sample cohorts.519 
Comparison of IHC staining evaluation from studies on TMAs and standard sections have 
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been done for various cancer types, with good correlation between results,520-522 although 
some studies have suggested a problem of selection bias since the area assessed is of 
larger impact when assessing location-dependent markers or markers that exhibits large 
degree of expression heterogeneity.523,524 In general, 2 or 3 cores each of diameter 6μm 
are recommended.522,525,526 The TMA method has been applied in our research group since 
2000.107,120,527 
 
It is recognized that FFPE tissue maintains antigenicity for several decades.522 However, 
researchers are recommended to ensure that staining intensity is not associated with the 
storage time of the archival material.517 We did not find any association between storage 
time of the FFPE tissue (categorized into 5-year periods) and staining index for 
pStathmin(S38) (IHC data from Paper IV), when IHC staining was performed 
simultaneously for samples in the two major patient cohorts (Figure 15, P=0.09). In a 
previous study by our group, no significant associations between staining index and 
fixation time was demonstrated for the biomarker Stathmin.298  
Figure 15. Comparison of the staining intensity in the two cohorts studied for 
pStathmin(S38) to evaluate potential effects from FFPE tissue block archival time on 
antigenicity.  
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Staining protocols: ERĮ and pStathmin(S38)  
 
How well the staining reflects the protein levels of the marker of interest depends 
amongst other factors on the antibody used (how specific the antibody binds to the 
epitope under study), the staining protocol used, and how the staining is evaluated.   
 
IHC assessment of the biomarkers ERĮ and pStathmin (S38) was performed on 5μm thick 
TMA sections of FFPE primary tumor samples. Previously published IHC data included 
in the study was assessed on standard or TMA sections.104,120,154,228,298 Sections were de-
waxed in xylene and rehydrated in alcohol in appropriate concentrations. In tissue 
formalin fixation, chemical bonds are created between proteins, potentially masking the 
epitope. Epitope retrieval can be achieved enzymatically (e.g. proteinase K, pepsin, 
trypsin) or by heat, the latter applied for the IHC studies in this project and also 
recommended used in IHC of FFPE tissue to minimize the epitope level variance due to 
variation in fixation time.528 Peroxidase activity block was performed by S2032 
DakoCytomation. Thereafter, samples were incubated with antibodies according to 
optimized and/or establish protocols (Table 12) developed under supervision of senior 
engineer Gerd Lillian Hallseth and consultant pathologist prof. Lars A. Akslen. 
EnVision+(K4006) DacoCytomation was applied for detection, with enzyme labeled 
polymer of the secondary antibody and DAB+ chromogen. Finally, the slides were 
counterstained with haematoxylin (Dako S2020). The IHC data except of ERĮ and 
pStathmin(S38) were performed by other researchers in the groups of prof. Salvesen and 
prof. Akslen and previously published as part of other studies (see references for primary 
publication for each marker in Table 12 – part B). The IHC protocol for pStathmin(S38), 
except for evaluation of the staining, was performed in the lab of OvaGene Oncology 
(Irvine CA, USA) under supervision of William Ricketts (scientist, founder and scientific 
officer at OvaGene Oncology). Tissue samples expected to express the epitope were used 
as positive controls. Negative controls were achieved by omitting the primary antibody, 
using diluent only. 
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Table 12. Immunohistochemical protocols. A: New to this project, B: previously 
published. 
A.             
Antibodya Epitope TMA/ 
Provider/Clone retreival Dilution Incubationb Detection Std. slide 
ERĮ Tris-a EDTA 1:50 30 min EnVision TMA 
Dako/ER50 MV 10' 750W, 
  20' 350W         
pStathmin(Ser38) Citrate, Bond  1:200 15 min  BondPolym TMA 
Cell Signaling/D19H10 Epitope Retreival 
Refine 
detect 
  Solution 1         
B.           
E-cadherin120 Citrate 1:400 Overnight LSAB Standard 
Zymed Laboratories/HECD-1 MW 10' 750W, 
  15' 500W         
ȕ-catenin120 Citrate 1:800 25 min LSAB Standard 
BD Transduction Lab./14 MW 10' 750W, 
  15' 500W         
P-cadherin120 TRS 1:100 60 min EnVision TMA 
BD Transduction Lab./56 MW 10' 750W, 
  15' 500W         
Catenin p120120 TRS 1:3200 60 min EnVision TMA 
BD Transduction Lab./98 MW 10' 750W, 
  15' 500W         
Stathmin298 Citrate 1:50 1hr EnVision TMA 
Cell Signaling/3352 MW 10' 750W, 
  15' 350W         
Ki67154 Citrate 1:50 1 hr LSAB Standard 
Dako/A-047 MW 7.5' 750W, 
  5' 500W         
 
Footnotes: a References to previously published data. b Incubation at room temperature if not otherwise 
specified. A) IHC method for ERĮ and pStathmin(Ser38) applied in Paper II and III. B) IHC for 
antibodies primarily evaluated and published in other studies. 
Abbreviations: LSAB=Labeled StreptAvidin Biotin. TMA=tissue microarray.  
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Evaluation of staining 
Various staining evaluation methods are applied in biomarker studies; e.g. percent stained 
of evaluable area and an H-score weighting differently weak to strong nuclear staining in 
the same sample.529 The National Cancer Institute and European Organisation for 
Research and Treatment of Cancer suggested the “Reporting Recommendations for 
Tumor Marker Prognostic Studies” (REMARK).515,530 In our research group, a staining 
index (SI) method for staining evaluation has been established in the group of L.A 
Akslen531,532 and has been applied over several years and in many studies, covering 
various cancer types.298,355,531-536 The staining index considers both staining intensity and 
the proportion of tumor cells with positive staining reaction. SI (0-9) is the product of 
staining intensity (0-3) and proportion immunopositive tumor cells (0%=0, <10%=1, 10-
50%=2, >50%=3). The method is subjective and semi-quantitative. Intra- and 
interobserver reproducibility have been evaluated in several studies, with good 
outcome.120,298,531,533,537 Also, in this project a subset of random TMA slides covering 210 
cases was evaluated for interobserver agreement for pStathmin(S38) staining evaluation 
between 2 of the authors on Paper III (H.B.S. and E.W.), blinded for each other’s 
evaluation results. Complete categorical agreement was found in 88% of the samples 
(Kappa value=0.7) which is considered good agreement between observers.538 
By including two staining measures (staining intensity and area stained), the SI method 
potentially better quantitates the amount of epitope bound by the antibody, as compared to 
evaluation of only one staining measure. This principle is also similar to the FDA-
approved criteria for HER2 assessment used in routine diagnsotics of breast cancer 
(Hercep Test).539 However, assessment of the SI applied in independent laboratories is yet 
to be done and such a “two-point” score index, and in particular the more subjective 
staining intensity measure, may contribute to reduced inter laboratory reproducibility, as 
seen for other score methods.540 A score method less subjectively influenced could 
potentially be more valuable in a routine setting. Follow-up studies comparing the score 
methods applied in the research setting and the routine setting should in that case be 
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performed. Digitalized image analysis including data on morphology is presented,541,542 
and time will show how well such methods perform in routine pathology. 
 
3.4 Gene expression data 
Cancer associated transcriptional alterations being important to cancer development are 
often preceded by genomic aberrations (e.g. copy number gain/loss, mutations). The 
genomic and the accompanying transcriptional alterations may potentially point to targets 
for therapy and may also predict therapy response. Gene expression data has also proved 
useful to classify cancer into molecularly defined subtypes,412 and the gene expression 
technology is regarded an important tool in cancer research.543 
 
DNA Oligonucleotide microarray  
In DNA oligonucleotide technology, total RNA is extracted and reversely transcribed to 
complementary DNA (cDNA) before amplified to cRNA. Fluorescently (Cy3) labeled 
ribonucleotides are incorporated in the cRNA in the amplification process. Labeled 
cRNAs are hybridized to complementary probes on a microarray slide. The strength of the 
fluorescent signal from a spot after hybridization depends on the amount of the sample 
cRNA that binds to the probes at this spot. Each spot signal was read by scanning the 
arrays using Agilent Microarray Scanner Bundle. The spot signals are processed by 
various measures (adjusting for background signal, replacing missing values, filtering 
spots and normalizing signal data) and thereafter represents the gene expression level for 
the genes present at the spots. In our study, the final gene expression levels were 
determined using J-Express (www.molmine.com) and BRB-ArrayTools 
(http://linus.nci.nih.gov/BRB-ArrayTools/).  
 
One-channel microarray technology is applied in this study (Agilent Whole Human 
Genome Microarrays 44k (Cat.no. G4112F)), where only one fluorescent dye is added to 
the samples and one sample is added per array. The expression levels for each gene are 
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indicated as a relative hybridization level for the current target. The expression values are 
not true measures for abundance, but are merely used to relate expression levels between 
classes; to compare expression levels between groups of samples processed in the same 
experiment.  
 
Gene expression profiling by microarray is today widely used in the search for 
transcriptional alterations and network-based interactions in cancer (Figure 16).543 The 
first DNA microarray study was described in 1995, assessing 45 genes in a plant 
(Arabidopsis thaliana).544 Both the microarray technology and areas of application have 
since then been extensively developed and standard gene expression microarray 
experiments assess thousands of genes; in the arrays we have applied, 44 000 probes 
cover 20-22 000 genes.  
  
Microarrays are performed on “simple” and “complex” systems, such as a cell lines and 
human cancer tissue, respectively.545 Sampling complex systems makes is more difficult 
to conclude on the origin of signals; does the increased expression of the gene of interest 
come from the epithelial or stromal cells, or from the vasculature interspersed amongst 
the other cells? Until recently, the cancer cells (the cancer epithelial cells when studying a 
carcinoma) have been the main focus in cancer research both when trying to reveal 
mechanisms for initiation and progression of cancer as well as targets for therapy. To 
optimize human cancer tissue sampling for genome wide analyses (e.g. SNP array, gene 
expression array), it has been regarded “good practice” to increase the proportion of the 
epithelial component by sampling cancer tissue with high tumor cell content, 
microscopically judged or by laser capture dissection (LCD) of epithelial cancer cells. In 
our microarray studies, the majority of samples have tumor content >80% 
(microscopically judged in frozen sections immediately adjacent to sections used for 
DNA and RNA extraction). A study by Halle et al demonstrated an association between 
high tumor cell content in snap frozen tissue and high histologic grade and other features 
of aggressive endometrial carcinomas and reduced survival.546 This demonstrates the 
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importance of biomarker validation in routine settings before applying research results in 
routine pathology and clinical practice. As tumor stroma has gotten extensively more 
attention in translational cancer research, separate gene expression assessment of these 
cells might be performed by LCD.547,548 
 
Figure 16. Pipeline of microarray analyses (Adapted  from545). 
                   
 
Probe selection 
Probe selection for whole gene expression microarrays, aiming for optimal specificity and 
sensitivity, often occurs through specialized design programs.549 Optimal probe design is 
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a compromise between specificity and sensitivity:550 Long oligonucleotide probes (50-80 
mers) are likely to cross-hybridize551,552 while short oligonucleotide probes (25-30 mers) 
are more likely to present with low signal intensity.553 The Agilent 44k arrays apply 
oligonucleotide probes, each consisting of approximately 60 nucleotides.   
 
Probes are designed with an “intelligent” purpose. However, it is recognized amongst 
users of microarray technology and analyses, that there are “good” probes and “bad” 
probes. An example: the ESR1 gene at the Agilent 44k array is covered by three different 
probes, each of them covering ~60 nucleotides of the ESR1 gene that in total is ~ 413k 
base pairs long. In our data, one of the probes does not associate significantly with ERĮ 
protein expression (by IHC) or with ESR1 mRNA by qPCR. The two other probes 
associate both with estrogen receptor Į protein and mRNA (qPCR) expression (Paper II). 
We further found that the one “outsider probe” did not vary to any extent between 
samples, while the other two probes did. Are we dealing with a “bad” probe? Or is the 
lack of association between this probe and ERĮ protein expression pointing to a biological 
explanation for this finding? One approach, if there are more than two probes, may be to 
examine how the expression values for each probe relates to the other probes, potentially 
adding an argument for these probes being particularly relevant as compared to a probe 
which expression did not associate with other probes for the candidate gene.   
 
Bioinformatics 
The field of bioinformatics has developed rapidly as the high-throughput analyses have 
become daily practice for many researchers. Bioinformatic tools are highly valuable when 
compiling clinical data and expression information about 44 000 probes covering 20-22 
000 unique genes for each tumor sample run on the arrays, and when trying to see some 
of the “stories” within the large amount of data. Such tools may aid to extract trustworthy 
and biologically meaningful information from the microarrays. Before data analysis, the 
raw data must be pre-processed. Background intensity and spots with low or difficult 
detectable signals must be removed. 
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Normalization 
Normalization is a major step before comparing gene expression values between arrays. 
There is likely an intensity imbalance between RNA samples not due to biological 
differences and true gene expression alterations between samples, but for reasons such as 
imbalance in RNA input or differences in uptake of dye.554 The goal of normalization is to 
ensure similar distribution of expression values across arrays and will facilitate the 
comparison of expression values between samples.554,555  
 
There are several different normalization methods – some more recognized than others. A 
way to find an appropriate normalization method is to test various methods and see how 
they affect the data and output. We have used median over entire array (Paper II) and 
quantile normalization (Paper III and IV).556 By normalizing data, we reduce the risk of 
false positive findings, but simultaneously introduce an increased risk of false negative 
findings, as we may dilute differences that were real, but adjusted so that the difference 
vanish in later analyses. This is an issue especially for genes with a low expression fold 
change between classes.  
 
Analyses of transcriptional alterations between samples    
Microarray analyses can be divided into unsupervised and supervised analyses. The 
former require no supplementary information to the expression data to be performed. The 
latter is driven by sample characteristics, typically in 2 groups (e.g. “positive” versus 
“negative” molecular phenotype, high versus low tumor stage). 
 
Unsupervised analyses and class discovery: 
By unsupervised analyses, without guidance by additional data except for the gene 
expression data itself, the aim of the methods is to find patterns in the expression profiles 
where no predefined class is presented. 
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Hierarchical clustering is an example of unsupervised analysis. This method aims to 
group together similar objects based on measures of similarity and dissimilarities between 
the objects.557 Hierarchical clustering requires specification of a similarity metrics and a 
linkage. The similarity metric describes how similar two samples are by reflecting the 
distance between two samples. Additional information for the distance between clusters is 
needed, and this is in the hierarchical cluster analyses reflected by the linkage method 
(single, average or complete linkage). Complete linkage are demonstrated to be superior 
for clustering genes,558 while for clustering of samples, both average and complete 
linkage is proven useful.554 Validation of the identified clusters is crucial, including 
validation of both biological and clinical plausibility and the level of statistical 
evidence.554 The hierarchical clustering is applied in Paper II, III and IV. 
 
Supervised analyses 
 
Single genes differentially expressed between groups 
Identifying genes with known function that are differentially expressed between two 
groups may provide better understanding of biological differences between the groups.554 
If the genes found are of unknown function, the analyses might provide insight into new 
gene functions. Supervised analyses require supplementary information about the groups, 
such as clinico-pathologic data or molecular phenotypic data. In Paper II and III, 
supervised analyses are performed based on ERĮ and pStathmin(S38) status. 
 
An increased risk of false positive findings due to multiple testing occurs as we run 20 
000 tests simultaneously on the same data, when searching for genes differentially 
expressed between classes. There are various methods to adjusting for multiple testing, all 
of them with the aim to give us certainty that the genes in our analysis output really are 
differentially expressed between the groups we examine, and not listed due to chance. 
Being very strict in the multiple testing adjustments might lead us to mask true biological 
effects. The adjustments will thus be a “trade-off” between too few and too many genes 
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correctly identified as differentially expressed between classes. It is generally accepted 
that adjusting to get no false positive genes in the output is a too stringent approach. If 
searching for single genes differentially expressed between classes, the genes identified 
should never the less be further validated, and elimination of potential candidate 
genes/biomarkers (false positives) occurs at these stages. A commonly used approach to 
adjust for multiple testing is to control the false positive discovery rate (FDR).559 In the 
Paper II and III we have adjusted for multiple testing by performing the class 
comparison analyses “Significance Analysis of Microarray” (SAM), where the FDR 
adjustment method is included.560  We have defined FDR <0.05 and FDR<0.1 as cut-off 
(Paper II and III, respectively), relatively stringent cut-off values, but for the purpose of 
our analyses we found it more important to reduce the risk of false positives than risk of 
false negatives.  
Gene Sets differentially expressed between classes   
To gain further insight into biological mechanisms involved, based on gene expression 
microarray data, is a major challenge when working on DNA microarray data.422 
Subramanian et al. pointed to a few highly relevant obstacles in how to interpret the 
single-gene lists into new and/or relevant biological information:422 We may miss 
information about pathways alterations by single gene analyses, as the interpretation of 
these are heavily depending on the researcher’s pre-knowledge in the field. Pathway 
signaling may involve large gene networks, and we should not be too focused on “large 
enough” fold changes of single genes in the search for biological information in our data 
output. Minor changes in all genes known to be involved in a signaling pathway may be 
of higher importance than large fold changes of a few genes.  
Gene Set Enrichment Analysis (GSEA), an online available tool 
(www.broadinstitute.org/gsea), is a method that determines whether an a priori defined 
set of genes shows statistically significant differences between two classes (e.g. 
phenotypes).  The Molecular Signatures Database (MSigDB) is a publically available 
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collection of five major classes of annotated gene sets 
(www.broadinstitute.org/gsea/msigdb) (Table 13) and is implemented in the GSEA.  
 
Table 13. Overview of the 5 major classes of gene sets in MSigDB 
(www.broadinstitute.org/gsea) 
    
Gene Sets  Description 
Positional  Gene sets corresponding to each human chromosome and each cytogenetic 
band has at least one gene 
Curated  Gene sets collected from various sources such as online pathway databases 
 (e.g. BioCarta, Kegg), publications listed in PubMed and from domain 
experts 
Motif  Gene sets that contain genes that share a cis-regulatory motif that is  
conserved across the human, mouse, rat, and dog genomes 
Computational Gene sets defined by mining large collections of cancer-oriented  
microarray data 
Gene ontology (GO) Gene sets named by their GO term and contain genes annotated by that term 
 
The gene expression signature applied in GSEA/ MSigDB are generated in various ways, 
and caution needs to be drawn when interpreting the results. To draw conclusions on gene 
set analyses, it is crucial to understand how the gene sets and signatures in question are 
generated and evaluate whether the gene set as generated is relevant for the current study. 
Also when exploring on gene sets alterations between classes like in GSEA, it is 
important to adjust for multiple testing, which we did by use of FDR (See above) (Paper 
II and III). Another gene set analysis (GSA), presented by Efron & Tibshirani561 (applied 
in Paper II) is a further development of the GSEA and suggested to present output with 
more strength than the statistics used in GSEA.554  
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Gene expression signature score 
Different approaches can be used to calculate a gene expression signature score, based on 
the expression values of the genes comprising the gene set/signature.415,512,562 For this, we 
have selected an established model where the signature genes are high level mean and 
variance normalized, and thereafter summarized to a score by subtracting the expression 
sum of down-regulated genes from the expression sum of up-regulated genes.415   
 
Connectivity Map 
Connectivity Map is a publically available drug signatures database 
(www.broadinstitute.org/cmap),424 and applied in Paper II, III and IV. The database is 
built up by treating different cancer cell lines with ~1300 different compounds, both FDA 
approved drugs and other bioactive compounds. The cell lines are treated with various 
compound concentrations and treatment durations. Cell line RNA is extracted and run at 
gene expression microarrays before and after the different therapy regimens, and genes 
differentially expressed between treated and non-treated cell lines comprises the 
“compound’s signature”. A gene signature from a specific study (e.g. our ERĮ negative 
gene expression signature, Paper II) is correlated to the compound signatures and given a 
“connectivity score”, indicating whether our signature of interest is positively or 
negatively associated with the various compound signatures (Figure 17). A ranked list of 
compound signatures with significant positive or negative correlation with our signature 
of interest is given.  
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Figure 17. Connectivity Map; schematic workflow. A. Genes differentially expressed 
between a cell line before and after treatment with one specific compound constitute the 
“compound signature”. Arrows up/down denotes genes higher/lower expressed in one cell line, 
compared to the other cell line (non-treated versus treated). B. The signature of ERĮ negative 
tumors is generated the same way. C. When running a candidate signature (e.g. the ERĮ negative 
signature) against all the compound signatures in Connectivity-Map (as exemplified by one 
signature in [*]), the candidate signature may positively [Alt 1] or negatively [Alt 2] associate 
with the compound signatures.  
 
115

Connectivity Map may serve as a hypothesis generating tool that aims to associate gene 
expression data, small molecules and disease states.424 By correlating a gene expression 
signature of interest to the drug signatures in the database, hypotheses of targets for 
therapy and pathophysiological processes can be derived. Limitations are present, such as 
few cell lines included in the test panel, limited number of concentrations tested, and 
maybe not a good enough correction for false positive findings, as the database has been 
extended from the first 164 compounds to more than 1300 compounds today. Also, it is 
important to remember that the hypotheses generated will need to be further tested to 
conclude on associations and potential relevance for new therapeutics. Due to the relative 
uncertainty related to where a signal of interest originates from, together with the issue of 
false positive findings due to multiple testing, validations of results from gene expression 
microarray studies are recommended. 
 
 
Quantitative polymerase chain reaction and relative quantitation of gene expression  
In polymerase chain reaction (PCR), total RNA is extracted from fresh frozen tumor 
tissue. RNA is thereafter converted to cDNA for hybridization with DNA oligonucleotide 
primers for gene(s) of interest. The cDNA product is doubled in cycles, aided by DNA 
polymerase and cycling of the primer and sample temperature. The PCR reaction consists 
of three different phases: 1) the exponential phase with a doubling of product at every 
cycle; 2) the linear phase - the reaction slows down; 3) the plateau, where no more 
products are being made (Figure 18).   
Unlike traditional PCR, which measures the amount of accumulated PCR product at the 
end of the PCR cycles, real-time qPCR measures PCR products as they accumulate during 
amplification. Two values are calculated during the qPCR run: 1) A threshold line/level of 
detection at which reaction reaches a fluorescent intensity above background in the 
exponential phase of amplification, 2) The PCR cycle number at which the sample 
reaches this level, called “Cycle threshold” (Ct) (Figure 18-B). The higher the RNA input 
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to the qPCR reaction, the fewer cycles are needed before the sample will reach its copy 
number threshold level and the numbers of cycles (Ct value) needed to reach this level is 
lower than for a sample with lower RNA input. 
In this project, we used qPCR to validate the mRNA expression of ESR1 and SERPINE-1 
(= PAI-1) from the DNA microarray (Paper II). We also assessed candidate genes linked 
to EMT by qPCR (Paper II) and the expression levels of the 29 genes in the endometrial 
cancer recurrence score, ECARS (Paper IV). 
 
Figure 18: Schematic picture of the copy number increase per cycle and the three phases 
of the qPCR (A) and examples of three genes with different cycle threshold (Ct) values.  
 
 
The qPCR was run in TaqMan© Low Density Arrays (LDAs). The LDAs are 
microfluidic cards with user-defined primers and probes, detecting mRNA levels of single 
genes from tumor. A sample of complex, atypical endometrial hyperplasia was used as 
calibrator. The genes’ expression levels were estimated based on the delta-delta-Ct 
method for relative quantitation of expression.563 
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The most optimal choice for calibrator for the relative quantitation is a sample where the 
gene expression variance across samples is low. The atypical hyperplasia was an 
appropriate calibrator for the genes assessed in these studies. GAPDH and ACTB were 
run as endogenous controls. We assessed which of the genes GAPDH and ACTB that was 
least associated with clinico-pathologic phenotype in the patient series assessed and 
GAPDH was applied in the relative quantitation as this varied least between samples. 
Several studies have reported on a panel of endogenous control in qPCR studies, selecting 
the best endogenous control for the specific experiment, the control gene depending on 
the experiment and the type of tissue being examined.564-566 With this knowledge in mind, 
our studies could potentially have benefitted from running a larger panel of endogenous 
controls, selecting the most appropriate one for each marker and study. 
 
 
3.5 DNA analyses  
Primary endometrial carcinoma tissue was examined by Single Nucleotide Polymorphism 
(SNP) arrays in a previous publication from the research group.79 These SNP array data 
were applied in this project (Paper II, III and IV). 
PIK3CA exon 9 and 20 was sequenced primarily in a study by Birkeland et al.71 These 
data were also applied in this project (Paper II, III and IV). 
PIK3CA copy number in primary tumors was examined by Fluorescent in situ 
hybridization (FISH) by project collaborators (F. Holst and R. Simon) (Paper III and 
IV).  
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3.6 Statistical methods  
Statistical analyses  
Statistical analyses have been performed, using SPSS 15 (Statistical package for social 
sciences 15.0) or PASW 18.0 (IMB, New York, USA). Associations between categories 
have been assessed by Pearson’s chi-square test, replaced by Fisher’s exact test when 
estimated expected count was <5. Comparison of continuous variables between categories 
was examined by Mann-Whitney U test. The Spearman rank correlation test was used for 
correlation analyses between two continuous variables.  
Comparing the survival pattern between groups (disease-specific, recurrence free 
survival) was performed by log-rank (Mantel-Cox) test. The Kaplan-Meier plot was 
applied to visualize survival and lifetime data. Multivariate survival analyses were 
performed by Cox’ proportional hazard regression method and the likelihood ratio test. 
Each variable was examined by log-minus-log plot before incorporation into the 
multivariate regression model to determine if the variable was appropriate to be included 
in the analysis. Unadjusted and multivariate adjusted hazard ratios (HR) were estimated. 
Tests for interactions were performed if regarded pertinent. Time of entry was similar to 
time of diagnosis, at primary surgery. The end-point was first recurrence or death from 
endometrial carcinoma, when assessing risk of recurrence or death from disease, 
respectively. All statistical tests were considered statistical significant if p<0.05 (except 
for the DNA microarray analyses, see separate section).   
Cut-off determination 
We scored the samples blinded for clinical data and outcome measures of the patient 
series under study, as recommended by the REMARK guidelines.530 To dichotomize 
continuous and ordinal/nominal variables (gene expression and IHC data), the variables 
were categorized by median and quartiles, as a quartile based cut-off (also for ERĮ) has 
been demonstrated useful and robust in various biomarker studies in previous publications 
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from the group,167,298,355,435 and is also a recommended approach without the risk of over 
fitting the cut-off point to the data examined.567 The number of events in the quartile 
groups was considered, and groups with similar survival pattern were eventually 
merged,568 rendering median or upper/lower quartile the cut-off point for the IHC 
variables assessed (Paper II and III), Table 14, while the median was chosen as cut-off 
for the endometrial carcinoma recurrence score (Paper IV).  
Table 14. Overview of IHC staining; localization of staining and cut-off definition. 
      
Antibody Standard slide  Staining localization Cut-off;  
or TMA percentile group/SI (high) 
ERĮ TMA Nuclear Lowest quartile/SI >0a 
pStathmin(S38) TMA Cytoplasmic Highest quartile/SI ш6 
Previously published data 
E-cadherin120 Standard slide Membranous Median/SI >3 
ȕ-catenin120 Standard slide Membranous Median/SI >2 
P-cadherin120 TMA Membranous Highest quartile/SI ш6 
Catenin p120120 TMA Membranous Lowest quartile/SI ш3 
Stathmin298 TMA Cytoplasmic Highest quartile/SI =9 
 
Footnotes: SI (high) = staining index defining “high expression”. TMA= Tissue microarray. a SI 
ш2 in prospective validation series (n=155, Paper II) and in qPCR validations series (n=158, 
Paper IV).  
 
3.7 Approvals 
This study has been approved by the Norwegian Data Inspectorate (961478-2), the 
Norwegian Social Science Data Service (15501) and the local Institutional Review Board 
(REKIII nr 052.01).  
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4. MAIN RESULTS 
Paper I  
The prognostic impact of DNA ploidy was investigated in endometrial carcinomas in a 
research setting (n=101) and compared to a routine diagnostic setting (n=262), with 
aneuploidy detected in 25% and 21%, respectively. Aneuploidy was associated with 
higher age at diagnosis, non-endometrioid histology and high histologic grade in both 
series studied. DNA ploidy was correlated to poorer survival in both uni- and multivariate 
survival analyses, adjusting for age, histologic subtype, histologic grade and FIGO stage, 
also in the routine diagnostic setting. Within the subgroup of FIGO stage I cases only, 
DNA ploidy was still associated with survival outcome in univariate survival analysis, 
when merging both data sets. Within FIGO stage I cases of the routine diagnostic series, 
DNA ploidy showed only borderline independent association with survival in multivariate 
survival analysis, adjusting for age, histologic subtype, histologic grade and myometrial 
infiltration.  In this study, we found the research and routine diagnostic series to be 
comparable, with no significant differences in distribution in the standardly applied 
clinico-pathological variables. 
 
Paper II  
We investigated 4 independent patient series and found ERĮ level to be an independent 
prognostic marker in endometrial carcinoma; low ERĮ expression was associated with 
age, non-endometrioid histology, high histologic grade, and high FIGO stage, as well as 
poor survival. The same pattern was seen in patient subgroups comprising cases with 
expected good survival, such as endometrioid grade 1 or 2 tumors only. ERĮ maintained 
its independent association with prognosis in multivariate survival analyses, adjusting for 
age, histologic subtype, histologic grade and FIGO stage. 
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Transcriptional differences based on ERĮ status revealed pathways, single genes and 
transcription factors linked to epithelial-mesenchymal transition (EMT) enriched in ERĮ 
negative tumors. These findings were validated in an external gene expression data set. 
The association between low ERĮ expression and EMT was further validated in two 
independent patient series; low ERĮ expression was significantly correlated to pathologic 
mRNA expression of the cell adhesion E-cadherin, catenin p120, catenin Į and catenin ȕ 
expression levels. Further, in a population based series, ERĮ negative 
immunohistochemical expression was associated with pathologic protein expression of E-
cadherin, P-cadherin, ȕ-catenin and catenin p120, as well as deep myometrial infiltration 
and vascular invasion.   
A generated EMT gene expression signature demonstrated that high signature score 
significantly correlated with aggressive endometrial cancer and poor survival in univariate 
and multivariate survival analyses, adjusting for age, histologic subtype, histologic grade 
and FIGO stage. 
ERĮ-low tumor status was also significantly correlated to various markers for PI3K 
pathway alterations including amplification of the 3q26 region harboring PIK3CA, 
PIK3CA/PTEN/AKT1 mRNA levels, high PI3K activation score and high Stathmin 
expression, although ERĮ did not significantly associate with presence of PIK3CA 
mutations in exon 9 or  20. When querying a drug signature database (Connectivity Map) 
for compound signatures significantly correlated to the gene expression signature of low 
ERĮ expression in two independent patient series, PI3K/mTOR inhibitor signatures were 
in both series top ranked amongst the negatively correlated compound signatures. 
 
Paper III  
The immunohistochemical expression of pStathmin(S38) associated with a clinico-
pathologic phenotype; high pStathmin(S38) was correlated to features of aggressive 
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tumors, as non-endometrioid histology, high histologic grade, and high FIGO stage. High 
pStathmin(S38) also correlated with shorter disease specific and recurrence free survival, 
in both the investigation and validation cohorts. Within subgroups of presumed good 
prognosis, high pStathmin(S38) was correlated to reduced survival. Furthermore, 
pStathmin(S38) was independently associated with prognosis in multivariate survival 
analyses of tumors confined to uterus, when adjusting for myometrial infiltration, 
histologic subtype and histologic grade. pStathmin(S38) and Stathmin expression levels 
were significantly correlated but pStathmin(S38) was stronger associated with disease 
specific survival than Stathmin, when assessing both markers in the Cox’ survival 
analysis, adjusting for histologic subtype, histologic grade and myometrial infiltration.  
The gene expression pattern related to pStathmin(S38) expression was analyzed, and  
gene sets related to cell cycle progression were observed enriched in pStathmin(S38)-high 
cases. pStathmin(S38) also correlated with a panel of established markers for tumor cell 
proliferation: Ki67, mitotic count and S-phase fraction, whereas high Stathmin level 
associated with high proliferation assessed by Ki67 and mitotic count.  
A pStathmin(S38)-high gene expression signature was negatively correlated with drug 
signatures representing effect of PI3K/mTOR and HSP90 inhibitors. Furthermore, high 
pStathmin(S38) correlated significantly with several potential markers for PI3K 
activation. 
 
Paper IV  
In this study, we validated the ability of the previously defined 29-gene signature79 to 
predict recurrence free and disease specific survival. The 29-gene signature score, now 
assessed by qPCR, validated to identify patients with increased risk of recurrence, also in 
patient subgroups with presumed favorable outcome. The 29-gene endometrial carcinoma 
recurrence score (ECARS) was also associated with clinico-pathologic data of aggressive 
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endometrial cancer. Also, the two patient clusters defined by the signature were 
associated with reduced survival when assessed by oligonucleotide microarray data in an 
independent cohort (n=65) and in the cohort originally identifying the signature (n=57), 
now with new generation oligonucleotide microarrays. ECARS also validated to predict 
overall survival in 324 cases from The Cancer Genome Atlas (TCGA) database. 
High ECARS was associated with vascular invasion and measures for EMT. Also, the 
signature score was significantly associated with potential measures for PI3K pathway 
activation; amplification of the 3q26 region harboring PIK3CA, high PIK3CA copy 
number assessed by FISH, high Stathmin, high PIK3CA mRNA, and high PI3K 
activation score.  
We also assessed how ECARS and our EMT score (Paper II) were distributed in 
metastatic (n=19) compared to primary tumors. Both the ECARS and EMT score were 
significantly higher in the metastatic lesions.     
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5. DISCUSSIONS OF RESULTS  
Endometrial carcinoma is a heterogeneous disease often early diagnosed and with overall 
good prognosis. However, 15-20% of patients with localized disease at diagnosis 
experience recurrences, with increased risk of cancer-related death. Also, patients may 
experience reduced quality of life due to early and late toxicity, specifically related to the 
cancer treatment. To better balance the risk of both under- and over-treatment, there is a 
need to develop methods to improve the identification of patients with high risk of 
recurrences and to tailor surgical adjuvant therapy. Today, prognostication is based 
largely on histopathologic parameters and surgical staging.30 In the locally advanced or 
metastatic setting, more effective and targeted systemic therapies are needed, as well as 
markers predicting response to such treatment.  
This study is based on four publications (Paper I-IV), focusing on validation of the 
prognostic potential of selected biomarkers in independent cohorts and in a routine 
setting. Furthermore, we explore new biomarkers and relate these to tumor biological 
processes and potentials for targeted therapies by exploring drug signatures associated 
with biomarkers present in aggressive endometrial cancer in particular. By this, we 
suggest markers to identify patient groups with higher risk of recurrence and cancer-
related death and also provide a rationale for potential relevant targets for therapy and 
predictive markers in endometrial carcinoma. We also add knowledge to parts of the 
tumor biology underlying aggressive endometrial carcinomas.  
 
5.1 Improved identification of patients with high risk of recurrence and 
cancer-related death 
Current clinical decision making in the treatment of endometrial carcinomas mainly relies 
on surgical FIGO stage, histologic subtype and histologic grade.30 Several biomarkers 
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have been demonstrated to predict survival in endometrial carcinoma, although none are 
yet applied clinically for risk stratification.30,148  
After the first identification of a prognostic biomarker, the next step recommended is 
validation in independent cohorts before prospective validation in a routine setting. 
Eventually, prospective validation of clinical applicability for treatment stratification is 
necessary before application in routine practice.569  
A prognostic impact of DNA ploidy is well-established in endometrial carcinoma, the 
aneuploid tumors being associated with reduced survival, also when adjusting for 
standard clinico-pathologic variables as age, FIGO stage, histologic subtype and 
histologic grade.148 In this study, we demonstrate DNA ploidy as a robust prognostic 
marker (Paper I), identifying aggressive endometrial carcinomas also when adjusting for 
standard clinico-pathologic variables applied for prognostication in the routine setting 
today.30 We further demonstrate the robustness of DNA ploidy as a prognostic marker 
when assessed in the routine setting in a pathology laboratory, as compared to the 
research setting, an important step in the staircase from research to clinical 
application.569,570      
Low ERĮ expression has been associated with features of aggressive endometrial 
carcinoma for several decades.123,353-355 Still, the marker is not routinely integrated to 
tailor surgical therapy or adjuvant treatment in endometrial cancer.237,336 We report a 
strong relation between low estrogen receptor expression (both ESR1 mRNA and ERĮ 
IHC expression) and features of aggressive disease and reduced survival (Paper II). For 
the primary investigation and retrospective validation series, ERĮ staining index (SI) was 
0 for the ERĮ-low cases, representing truly ERĮ negative cases. For the prospective 
validation cohort, the ERĮ-low cases were identified by SI3, the same cut-off point also 
seen for a large multi-center study on ERĮ immunostaining in curettage specimens 
(Trovik et al, unpublished data). Less inter-observer variation is expected when reporting 
on the levels of an immunomarker where the cut-off is based on no expression versus any 
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expression, as compared to the cut-off point based on “weak” versus “strong” expression. 
If bringing ERĮ as prognostic biomarker closer to clinical application in endometrial 
cancer, further studies are needed to define ERĮ-low cases.  
Biomarker signatures (e.g. sets of gene or protein expression values or mutation status for 
a range of genes) are suggested to be of value for improved molecular classification and 
identification of risk-groups, as published in specific cancer types,411-413,571 and also 
recently demonstrated for endometrial carcinoma.79,572,573 Gene expression signatures are 
favored as prognostic markers, potentially reflecting a more complex part of the biology 
in “one go”, as compared to single protein biomarkers.543 Two gene expression signatures 
(MammaPrint and Oncotype Dx) are approved for clinical utility in breast cancer, 
predicting risk of recurrence and metastatic disease, and utilized to direct adjuvant 
therapy to high-risk cases.412,574 A previously published 29-gene endometrial carcinoma 
signature, associating with potential measures for PI3K activation and predicting disease 
relapse,79 was here validated in three prospectively collected patient series, independent 
from the series originally identifying the signature (Paper IV). The signature validated to 
associate with features of aggressive endometrial carcinoma and to predict risk of 
recurrence, also in patient subgroups with expected good prognosis, hence named 
Endometrial Carcinoma Recurrence Score (ECARS). 
Stathmin, a known microtubule destabilizer, is previously reported as a prognostic marker 
in breast and urothelial cancer,575,576 and high Stathmin is found to predict lymph node 
metastases, features of aggressive disease and reduced survival in our patient series.298 
Phospho-Stathmin(S38), one of the four Stathmin phospho-sites known to inactivate the 
Stathmin function, is previously not studied as a prognostic marker in any cancer type,153 
although explored in experimental models, mainly in relation to the effect on microtubule 
formation, proliferation, cell migration and cancer invasion.153,577,578 We here 
demonstrated the ability of pStathmin(S38) immunostaining to identify aggressive 
endometrial carcinoma, risk of recurrence and cancer-related death, also in patient 
subgroups with expected good prognosis (Paper III). pStathmin(S38) adds prognostic 
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information to Stathmin. As this is a first exploration of a new prognostic biomarker, 
although assessed in two independent patient series, further validation in cohorts from 
other hospitals and with IHC assessment in other labs are needed to conclude on the 
strength and robustness of pStathmin(S38) as prognostic marker in endometrial 
carcinomas, and its potential applicability in a routine clinical setting. 
 
5.2 Epithelial-mesenchymal transition (EMT) in aggressive endometrial 
carcinoma 
Through supervised analyses of transcriptional alterations between tumors with low 
versus high ERĮ expression (IHC), we identified an association between ERĮ negative 
tumors and EMT (Paper II). This was a consistent finding also validated in independent 
patient cohorts and by various EMT measures. Although an association between low ERĮ 
and Snail expression is previously published,212 our study is to date the most 
comprehensive study to demonstrate the association between ERĮ negative endometrial 
carcinoma and EMT. Tumors with low ERĮ expression were also associated with deep 
myometrial infiltration and vascular invasion, underlining the invasive characteristics 
amongst the ERĮ-low and EMT-positive tumors in this study. Pathologically altered IHC 
expression of the cell adhesion/EMT markers applied in Paper II (retrospective cohort) 
are in a previous study associated with features of aggressive endometrial carcinoma and 
reduced survival.120 Several recent studies have described an importance of EMT in 
endometrial cancer,89,129,579,580 and a study by Tanaka et al defined EMT status as low E-
cadherin and concurrent nuclear Snail expression (assessed by IHC) and demonstrated an 
association between EMT status, features of aggressive endometrial carcinoma and 
reduced survival.580 In line with this, we identified a curated EMT gene expression 
signature associated with reduced cancer specific and recurrence free survival (Paper II). 
This EMT signature demonstrated a superior ability to predict poor outcome to the 
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mRNA expression of single genes reported to be involved in EMT, adjusting for age, 
FIGO stage, histologic subtype and histologic grade. 
Also, high levels of the previously reported Endometrial Carcinoma Recurrence Score 
(ECARS) associated with several measures for EMT: high EMT score, altered mRNA 
expression of a panel of cell adhesion/EMT markers, deep myometrial infiltration, 
vascular invasion, and a vascular invasion gene expression score, supporting that high 
levels of ECARS also reflects presence of EMT and tumor invasiveness (Paper IV). 
Some of the single genes in ECARS are in the literature linked to tumor invasive 
properties, while other genes are more linked to tumor cell proliferation, potentially 
contributing to catch various aspects of the tumor biologic processes involved to develop 
the aggressive features seen in ECARS-high cases. 
From supervised analyses identifying differentially expressed genes and gene sets 
between ERĮ negative and positive tumors, a signature indicating TGF-ȕ signaling was 
enriched in ERĮ negative tumors. Furthermore, PAI-1 (=SERPINE-1) mRNA expression, 
a suggested marker for TGF-ȕ signaling,134 was significantly higher expressed in ERĮ 
negative cases, also validated in an independent patient cohort. High PAI-1 expression is 
shown to be associated with features of aggressive endometrial carcinoma and reduced 
survival.135-137 TGF-ȕ is regarded a major player in EMT and the invasive and metastatic 
process,127,581 and our findings may imply a role for TGF-ȕ also in aggressive endometrial 
cancer, as supported by other studies.129,130  
Is low ERĮ contributing to drive EMT activation? Breast cancer cell line studies have 
demonstrated that loss of ERĮ induces Snail and Slug expression, E-cadherin is 
subsequently repressed and a mesenchymal-like phenotype and increased invasive 
properties have been observed.582,583 A similar causality may be active in endometrial 
carcinoma. Also, it may well be that not low ERĮ in itself but a third party is the “driver” 
of EMT activation in our study, and with low ERĮ expression only co-occurring with 
EMT activation. In a study by Dhasarathy et al. on breast cancer cell lines, TGF-ȕ 
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signaling was demonstrated to be linked to Snail expression, and Snail had the ability to 
repress ERĮ.584 If this is the scenario also in our study, TGF-ȕ renders a potential key 
player in EMT activation in our setting. Further functional studies are needed to elucidate 
potential links between low ERĮ, TGF-ȕ and EMT in endometrial carcinoma. 
It is generally accepted that the EMT program is somehow “inactivated” once the 
metastatic tumor cells reside in the new microenvironment, lacking the signals from the 
surrounding stroma that initiated EMT in the primary tumor, thus reverting from the 
induced mesenchymal like back to the epithelial phenotype (mesenchymal-epithelial 
transition, MET).127 However, when examining the mRNA sum score of the curated EMT 
signature in primary and metastatic tumors, we found the score significantly increased 
from primary to metastatic lesions (Paper IV). Genes that constitute our EMT signature 
may contribute in a manner facilitating the growth of the metastatic tumors in the new 
environment, as exemplified by deletion of catenin p120 that in a recent study was 
demonstrated to have a potential as a regulator of inflammation in the tumor 
microenvironment,585 and thereby being potentially important for the metastatic 
colonization. One previous study comparing the levels of EMT markers in primary and 
metastatic endometrial carcinomas did not demonstrate any significant change in E-
cadherin, Snail and Slug protein expression by immunohistochemistry.580 
 
5.3 Potential targets and accompanying predictive biomarkers 
By examining associations between drug signatures from a publically available 
database424 and transcription signatures of molecular phenotypes related to biomarkers 
associated with aggressive endometrial carcinomas (ER negative, pStathmin(S38)-high 
cases), we identified targets such as PI3K/mTOR and HSP90 potentially relevant to these 
molecular subtypes of endometrial carcinoma (Paper II and III). Also, PI3K/mTOR is 
suggested as target in ECARS-high cases in the publication identifying this recurrence 
score.79 Based on identified biological processes and signaling pathways, we also suggest 
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TGF-ȕ signaling and elements of the EMT program as potentially relevant targets in 
aggressive endometrial cancer (Paper II and IV). The majority of ongoing clinical trials 
in endometrial carcinoma target PI3K/AKT/mTOR (see Table 8, chpt 1.8).  
Both TGF-ȕ and EMT are regarded relevant targets in cancer today,586 and response to 
inhibitors of these are presently being evaluated (www.clinicaltrials.gov, Feb 2013).586,587 
Based on the positive correlations between the biomarkers ERĮ and ECARS and 
measures for TGF-ȕ signaling and EMT, we suggest to explore the potential of ERĮ and 
ECARS as predictive markers to TGF-ȕ and EMT inhibiting therapy in endometrial 
carcinoma. Our data provide a rational for this to be tested in relevant clinical trials 
(Paper II and IV). Inhibition of HSP90, as suggested for pStathmin(S38)-high cases 
(Paper III), is also amongst promising drugs entering clinical trials in cancer treatment 
today. Increased expression of HSP90 allows tumor cells to cope with an imbalanced 
signaling in cancer, with demonstrated enhanced cancer cell survival.450 HSP90 inhibitors 
are presently in clinical trials for various cancer types (www.clinicaltrials.gov, December 
2012). Potential measures for HSP90 activity are not assessed in this study, as done for 
EMT and TGF-ȕ. Thus, a next relevant step may be to explore HSP90 expression in 
endometrial carcinomas. 
PI3K/mTOR signaling; suggested targets and predictive biomarkers 
The level of understanding of the biology related to the target and how the drug interacts 
with the target itself and its related biology is regarded critical in drug development.569 
This also applies to the development of relevant and robust predictive biomarkers, 
together with the robustness of the biomarker assay.569 Inhibition of the PI3K signaling 
pathway in cancer has been in focus during the last decade,92,588 also for endometrial 
carcinoma where PI3K/mTOR signaling is suggested as a relevant target.64,79,589 It has 
been a challenge to identify markers for PI3K signaling activity in tumor specimens, and 
thereby also relevant predictive biomarkers accompanying PI3K inhibitors. PIK3CA 
mutations are frequently associated with PI3K activation,72 although other PI3K pathway 
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alterations also are suggested as relevant measures.590 Gene expression signatures are also 
indicated to reflect PI3K pathway activation,591,592 the Endometrial Carcinoma Recurrence 
Scores being associated with one of these.79  
PIK3CA mutations are recently supported as potential predictive markers in various 
cancer types, including endometrial carcinoma,72,73,403,593 with the H1047R mutation being 
associated specifically with response to PI3K/mTOR/AKT inhibitors.73 PIK3CA 
mutations are found both in endometrioid and non-endometrioid subtypes, with a 
tendency of higher frequency in the type I carcinomas.64,72 We did not find a significant 
association between PIK3CA mutations and the biomarkers assessed in this study (ERĮ, 
pStathmin(S38) and ECARS), neither when assessing specifically the H1047R mutation. 
However, low ERĮ, high pStathmin(S38) and high ECARS are all associated with various 
other potential markers for PI3K pathway activation (Paper II-IV), and we have 
therefore suggested PI3K/mTOR inhibitors to these patient subsets 
Amplification of the 3q26 region has been associated with type II cancer (non-
endometrioid histology, high histologic grade, high FIGO stage).79 An endometrial cancer 
cell line study demonstrated estradiol driven PI3K signaling through both ERĮ dependent 
and independent mechanisms,145 supporting a potential for PI3K inhibition also in ERĮ 
negative tumors, supporting our findings and suggestions (Paper II). Phosphorylation of 
Stathmin is suggested linked to the PI3K pathway,594 supported by functional studies 
demonstrating Stathmin phosphorylation by PAK1.595 This supports relevance to our 
finding of an association between pStathmin(S38)-high cases and potential measures for 
PI3K pathway activation (Paper III). 
By our study, we propose a rationale for exploring the potential of ERĮ, pStathmin(S38) 
and ECARS as predictive markers for inhibitors of the PI3K pathway in endometrial 
carcinoma. In breast cancer, patients with the triple negative (ERĮ, PR and Her2 negative) 
and basal-like molecular phenotype is frequently included in clinical trials of various 
targeted therapies, not always due to a well-defined target demonstrated in this cancer 
132

subtype, but simply because the triple negative/basal-like cancer is an aggressive subtype. 
The same approach could potentially be applied for ERĮ negative endometrial 
carcinomas, also supported by the molecular findings associated with the low ERĮ in 
these tumors.  
Combinatorial therapy (strategies) 
Activated signaling pathways are complex processes, and often more than one pathway 
may activate a downstream target and affect the ‘end-stage’ biological processes driving 
the cancer disease. If targeted mono-therapy blocks for example a receptor tyrosine 
kinase, alternative signaling pathways may be activated leading to resistance.596 This, 
together with the challenges of intratumor heterogeneity,504 tumor cell evolution509 and 
drug resistance (de novo and acquired) require development of more complex regimens 
including combinatorial therapy.597 Combined drug therapies may be classified as 
“horizontal” (across two pathways) or “vertical” (within one oncogenic pathway).597 
Targeting a receptor and a protein downstream in the transduction pathway, such as done 
in dual inhibition of PI3K and mTOR, is an example of such “vertical” inhibition.593 
There are several combinations of molecularly targeted drugs in phase I trials today,597 
and a “vertical” combination of Everolimus (mTOR inhibitor) and Trastuzumab (Her2 
inhibitor) given together with Vinorelbine (anti-mitotic chemotherapy) is today in phase 
III trials in Her2 positive breast cancer. A combination of molecularly targeted drugs and 
conventional chemotherapy therapy has proven useful in several cancer types, including 
breast and colorectal cancer.598,599  This combinatorial strategy has partially been driven 
as a means to gain regulatory approval for drugs in diseases where conventional therapy is 
established.597 
We identify several potential targets for therapy in aggressive endometrial carcinoma 
(Paper II-IV). As EMT and also TGF-ȕ itself are suggested important in drug 
resistance,600 these are potentially relevant targets for therapy in combinatorial treatment. 
HSP90 is required for correct folding of AKT1 and PDK1,601 and is as such important to 
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PI3K signaling. Combining HSP90 and PI3K/mTOR inhibitors could be relevant in 
endometrial carcinoma. A study in metastatic gastric cancer is about to be started with 
such a therapeutic regimen (www.clinicaltrials.gov, ID: NCT01613950). HSP90 
inhibitors are designed to affect multiple oncogenic client proteins and may block several 
cancer-supporting signal transduction pathways597 and are highly relevant as co-drugs in 
combinatorial therapy regimens. Also, other combinations of inhibition of the targets we 
identify in aggressive endometrial carcinomas should be further explored.  
It has been suggested to apply panels of markers to better catch the biological alterations 
associated with therapy response to specific drugs,569 and gene expression signatures may 
be examples of such.436 In line with this, ECARS may be a relevant predictive marker also 
in combinatorial therapy regimens. Still, a panel of IHC markers may represent more 
robust and clinically applicable predictive marker, and ERĮ and pStathmin(S38) may 
contribute to such a panel. 
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6. CONCLUSIONS  
1. DNA aneuploidy identifies aggressive endometrial carcinoma and predicts poor 
outcome, also in a routine clinical setting (Paper I). 
 
2. Low ERĮ in endometrial carcinoma is associated with epithelial-mesenchymal 
transition, vascular invasion and PI3K alterations (Paper II).     
 
3. High pStathmin(S38) associates with high tumor cell proliferation and potential 
measures for PI3K pathway activation in endometrial carcinomas (Paper III). 
 
4. The endometrial carcinoma recurrence score (ECARS) validates to identify 
endometrial carcinomas with shorter recurrence free survival. ECARS increases 
from primary to metastatic lesions and is associated with potential measures for 
PI3K activation and epithelial-mesenchymal transition (Paper IV).  
 
5. Low ERĮ, high pStathmin(S38) and high ECARS predict aggressive endometrial 
carcinomas and reduced survival, and may suggest treatment with PI3K/mTOR 
and/or EMT inhibitors in clinical trials (Paper II, III and IV). 

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7. FUTURE PERSPECTIVES 
“It’s not that I’m so smart, it’s just that I stay with it longer.” (A. Einstein, 1879-1955) 
7.1 Potential ways forward 
We stand back with the key questions to answer in the further development of 
personalized therapy: What is a relevant target? Is the target druggable? How to identify 
and test intelligent combinatorial therapy regimens? And last but not at all least: Which 
biomarkers match the right patient and the right drugs?  
Both better identification of relevant targets and development of robust predictive 
markers are recognized as important issues to improve survival through more targeted 
cancer therapies.444 Development of new drugs is time-consuming and costly. 
Development of robust, testable and valid biological hypotheses, where the target in 
question is altered in the cancer, and targetable in tumor cells more than normal cells, are 
suggested as a critical elements to promote successful drug development.438 
Systems biology approach 
Our understanding of how the cancer cells function in comparison to normal cells is 
incomplete; the biology is complex and all research done has revealed probably only parts 
of what is driving cancer. By combining data from various ‘omics (e.g. genomics, 
transcriptomics, proteomics, metabolomics), systems biology may reveal more of the 
complex biological networks that are taking place in cancer cells, and potentially point to 
“nodes” of major importance for tumor initiation and progression.602-604 This systems 
biology approach, through high-throughput profiling, computational tools and 
experimental validation, is ongoing, addressing the challenge of biological complexity 
and aid in developing “network” therapeutic strategies and intelligent combinatorial 
therapies.438,464  
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Fast track accelerated biomarker testing and drug approval  
The development of Trastuzumab took ~25 years to be approved for adjuvant therapy to 
Her2 positive cases after the Her2/neu gene first was identified (www.fda.gov).605 To 
ensure faster progression from target discovery to clinical trials and clinical 
implementation for promising drugs, a “Fast Track” accelerated approval and priority 
review has been introduced. This will accelerate the availability of new drugs for patients 
with deadly and disabling diseases (www.fda.gov). One successful example of this is the 
approval of vemurafinib to patients with BRAF mutated melanomas only 9 years after the 
BRAF mutation was first published.439,606 Furthermore, a new set-up for clinical trials has 
been proposed; biomarker driven and hypothesis testing trials, where the three phases of 
the trials are more flexible and adaptive in their performance, depending on clinical and 
molecular data gathered:438   
Phase I/Proof of mechanism: Determine the optimal dose (range and schedule) to achieve 
sufficient target blockade. 
Phase II/Proof of concept: Evaluate the antitumor activity and the potential of predictive 
biomarkers in selected populations. 
Phase III/Pharmacogenomics: To identify which patients needs which therapy 
doses/schedules by assessing inter-patient variability  
Alternative models of clinical trials have recently been published, enriching for patients 
with tumors of a molecular genotype.403,593 Phase II-III trials have been presented with the 
aim to match the drug(s) studied with molecularly defined tumor subsets, not only to 
patients with advanced disease.607-609 
“Joint efforts” 
By combining the RNAi screen of cancer cell lines and an ‘omics approach to human 
tumors and large cell line panels, together with functional validation in appropriate 
models, and also taking the potential strength of signatures into account (both for pointing 
to targets and as predictive markers), together with “fast track” adaptive designed clinical 
137

trials, we may be approaching good input to and improved output from the strategies to 
personalize cancer therapy. Also, accounting for the intratumor heterogeneity and tumor 
cell evolution that takes place, will be important elements in the future strategies of 
personalized medicine (Figure 19). 
Figure 19. Schematic overview of applied and suggested methods for target 
identification, drug and biomarker development and a suggested path to clinical use.                             
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7.2 Suggestions to follow-up studies 
“… something is happening here, but you don’t know what it is. Do you, Mr. Jones?” 
(Bob Dylan, 1941- )  
In the following are suggestions of follow-up studies to this PhD project. These are 
probably tiny steps in the large puzzle of “how to fight cancer”, but to re-phrase Neil 
Armstrong: a small step from a study might lead to a giant leap for mankind…:  
Clinical implementation of biomarkers to define risk for recurrence 
DNA ploidy is repeatedly demonstrated as prognostic marker in endometrial cancer. A 
prospective multicenter study exploring on the ability of DNA ploidy to predict outcome, 
and the potential of DNA ploidy to identify patient subgroups that per today are regarded 
“good prognosis cases” (defined by standard clinico-pathologic data) could be a valuable 
add to individualize surgery and the risk stratification for adjuvant therapy. Also, 
concurrent assay exploration would be a relevant addition to such a study.  Assessment of 
the ability of DNA ploidy to predict response to radiation therapy and also other therapies 
would be relevant elements of studies exploring the potential of DNA ploidy as 
prognostic and predictive marker. 
We and others have demonstrated that low ERĮ expression is associated with aggressive 
endometrial cancer and reduced survival. The time has come to perform a prospective 
implementation study on ERĮ as prognostic marker in endometrial cancer, preferably in a 
multicenter setting. Exploration of immunostaining methods and determination of cut-off 
(positive/negative) would be important elements in such a study.  
Identification of new targets for therapy 
As a follow-up on the link between TGF-ȕ/PAI-1 and aggressive endometrial cancer 
demonstrated in Paper II, it would be interesting to explore on the role of these and other 
microenvironment elements in endometrial cancer progression, and their potential as 
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targets for therapy. Furthermore, the functional role of ERĮ in this setting would also be 
relevant to study.  
Further exploration of individual genes in the 29-gene ECARS (Paper IV), their 
association with the cancer hallmarks and their ability to drive cancer progression may 
contribute to target development and further strengthen the potential of ECARS as 
predictive marker.  
Identification of predictive markers for response to therapy 
Based on transcriptional tumor alterations, we have shown that ERĮ, pStathmin(S38) and 
ECARS status may suggest different targets for treatment, including PI3K/mTOR. A 
natural follow-up to this is would be to assess the potential of these markers to predict 
response to PI3K/mTOR inhibitors. A first step could be to assess the levels of the 
markers in tumor samples from clinical trials on the mentioned inhibitors. If ERĮ, 
pStathmin(S38) and/or ECARS status predict response, a “second level” study would be 
to enrich for endometrial cancer patients with present relevant markers to in randomized 
clinical trials of the candidate inhibitor. This will potentially increase the likelihood of 
significant effect from given therapy in randomized clinical trials with smaller sample 
sizes. Furthermore, we suggest similar exploration in clinical trials of the ability of 
pStathmin(S38) to predict response to HSP90 inhibitors.  
As Stathmin has been suggested as a marker for response to Taxanes in breast 
cancer,610,611 it would be interesting to investigate the potential of pStathmin(S38) alone 
and together with Stathmin to predict response to Taxanes in endometrial cancer and 
other cancers.    
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ERRATA 
Material and Methodological considerations: Figure 14, page 94.Number of cases with 
IHC in 2001-2011 patient series: “534” should read “518” 
Reference #498:  “N.C, S.M, P.S et al: A phase II trial of the mTOR inhibitor AP23573 
as a single agent in advanced endometrial cancer. J Clin Oncol, ASCO Ann Meet Proc 
2007.:2518Sabstract 5516, 2007” should read “Colombo N, McMeekin S, Schwartz P, et 
al: A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced 
endometrial cancer. J Clin Oncol, ASCO Ann Meet Proc 2007:Abstract No 18S, 2007” 
Reference # 513: “(TCGA) TCGA: Integrated Genomic Characetrization of Endometrial 
Carcinoma. Nature 2013, in press” should read “(TCGA) TCGA: Integrated Genomic 
Characetrization of Endometrial Carcinoma.” 
Reference # 559: “Y.B, Y.H: Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. Journal of The Royal Statistical Society 57:11, 
1995” should read ”Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A 
Practical and Powerful Approach to Multiple Testing. Journal of The Royal Statistical 
Society 57:289-300, 1995” 
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